: The AMEDEO Literature Guide

Home The Word Brain	My Amedeo FAQ Privacy About
	Amedeo Chinese For Medical Students & Physicians A complete 20-lesson, 300-page Chinese course with a companion app in 21 languages — free forever. Download the free PDF: Amedeo Chinese PDF

Lung Cancer

Free Subscription

Articles published in J Thorac Oncol
Retrieve available abstracts of 467 articles:
HTML format

Single Articles

July 2026

CANI M, Bafunno D, Caumo F, Novello S, et al
Cytisine for Smoking Cessation Within a Lung Cancer Screening Program: Results From the Italian RISP Trial.
J Thorac Oncol. 2026 Jul 6:104071. doi: 10.1016/j.jtho.2026.104071.
PubMed Abstract available

LEE JY, Kim S, Na KJ, Goo JM, et al
Germline Mutations as Risk Factors for Lung Cancer: A Systematic Review and Meta-analysis.
J Thorac Oncol. 2026 Jul 6:104069. doi: 10.1016/j.jtho.2026.104069.
PubMed Abstract available

ALLGAUER M, Kluck K, Kazdal D, Budczies J, et al
A Response to the Letter to the Editor: Population-informed Assessment of Clonality in Lung Cancer.
J Thorac Oncol. 2026;21:103725.
PubMed

SETHAKORN N, Chiang AC
Leveraging Vulnerabilities of Molecular Subtypes to Identify Rational Combination Therapies-The Next Wave in Extensive-Stage SCLC?
J Thorac Oncol. 2026;21:103898.
PubMed Abstract available

INAMURA K, Oka A, Todo S, Muto-Ishizuka M, et al
Methodological Considerations in Bioinformatics-Based Staging of Multifocal Lung Cancer.
J Thorac Oncol. 2026;21:103684.
PubMed

RYAN DT, Shah R, Ridge CA
Interventional Radiology and Thoracic Oncology: 20 Years of Innovation.
J Thorac Oncol. 2026;21:103890.
PubMed Abstract available

SALLE FG, Beasley MB, Brcic L, Cooper W, et al
Update on Pleural Epithelioid Mesothelioma: New Insights for Diagnosis and Patient Management.
J Thorac Oncol. 2026;21:103720.
PubMed Abstract available

SAW SPL, Li MSC, Park S, Hatano H, et al
Targeting MET in EGFR-Mutated NSCLC.
J Thorac Oncol. 2026;21:103711.
PubMed Abstract available

LEVY B, Paz-Ares L, Lin CC, Herbert S, et al
Datopotamab Deruxtecan Plus Pembrolizumab With or Without Platinum-Based Chemotherapy for Advanced or Metastatic NSCLC: The Phase Ib TROPION-Lung02 Trial.
J Thorac Oncol. 2026;21:103688.
PubMed Abstract available

TORASAWA M, Shukuya T, Huang J, Nagai R, et al
Tumor Inflammation-Associated Neurotoxicity Masquerading as Severe Immune Effector Cell-Associated Neurotoxicity Syndrome in a Patient With SCLC Treated With Tarlatamab: A Case Report.
J Thorac Oncol. 2026;21:103649.
PubMed Abstract available

BOOTH A, Hillman S, Laumann K, Zhao YQ, et al
PROSPECT-LUNG: A National Clinical Trials Network Trial Advancing Pragmatic Innovation in Cancer Clinical Trials.
J Thorac Oncol. 2026;21:103650.
PubMed Abstract available

DI FEDERICO A, Hong L, Elkrief A, Thummalapalli R, et al
TTF-1 Expression in Lung Adenocarcinoma: Clinicopathologic, Genomic, and Immunophenotypic Correlates and Outcomes to Immunotherapy-Based Treatments and KRAS(G12C) Inhibitors.
J Thorac Oncol. 2026;21:103610.
PubMed Abstract available

June 2026

DACIC S, Shenker D, Redman M, Brunner L, et al
Machine learning assessment of pathologic response in lung cancer resections after neoadjuvant therapy - IASLC MPR Project.
J Thorac Oncol. 2026 Jun 1:103953. doi: 10.1016/j.jtho.2026.103953.
PubMed Abstract available

STONE E, Hu X, Afriyie-Mensah JS, Lee P, et al
Advances in Diagnosis-Pulmonology.
J Thorac Oncol. 2026;21:103648.
PubMed Abstract available

SINGH AK
Blood-Based Biomarkers as Adjuncts to Computed Tomography Screening for Lung Cancer: Is the Rubber Ready for the Road?
J Thorac Oncol. 2026;21:103694.
PubMed

FAN Y, Zhao Y, Huang D, Zhao J, et al
First-Line Tislelizumab Plus Chemotherapy Versus Placebo Plus Chemotherapy in Extensive-Stage SCLC: A Long-Term Survival and Programmed Death-Ligand 1 Subgroup Analysis From the Randomized, Phase 3 RATIONALE-312 Trial.
J Thorac Oncol. 2026;21:103655.
PubMed Abstract available

FENG J, Khan S, Waddell TK, Yasufuku K, et al
Identifying Patients With High-Risk Stage I NSCLC Using a Tumor-Informed Plasma ctDNA Assay.
J Thorac Oncol. 2026;21:103645.
PubMed Abstract available

NILSSON MB, Le X, Poteete A, Yu X, et al
Loss of Payload Sensitivity and Other Mechanisms of Resistance to T-DXd in HER2-Mutant NSCLC: Implications for Subsequent Responsiveness to HER2 TKIs.
J Thorac Oncol. 2026;21:103555.
PubMed Abstract available

May 2026

KATSUMATA S, Kamigaichi A, Akamine T, Isaka M, et al
Segmentectomy versus lobectomy in non-small-cell lung cancer with pathologically invasive features: a post-hoc supplementary analysis of a multicenter, Phase 3 trial JCOG0802/WJOG4607L.
J Thorac Oncol. 2026 May 11:103916. doi: 10.1016/j.jtho.2026.103916.
PubMed Abstract available

DEL RIO B, Masini S, Caceres-Galvis C, Torres-Jimenez J, et al
Emerging Targeted Therapies for HER2-mutant Non-Small Cell Lung Cancer.
J Thorac Oncol. 2026 May 2:103899. doi: 10.1016/j.jtho.2026.103899.
PubMed Abstract available

D'ANGELILLO RM, Ramella S
Heart-Sparing Radiotherapy in Patients With Lung Cancer.
J Thorac Oncol. 2026;21:103612.
PubMed

ERASMUS JJ, Vlahos I
Advances in Radiological Imaging for Thoracic Oncology: A 20-Year Perspective.
J Thorac Oncol. 2026;21:103563.
PubMed Abstract available

TAFENZI HA, Essadi I, Belbaraka R
Lung Cancer in Morocco.
J Thorac Oncol. 2026;21:103561.
PubMed Abstract available

TUMINELLO S, Joyama Y, Taioli E
Genetic Predisposition to Lung Cancer Is Modulated by Sex, Smoking, and Ancestry.
J Thorac Oncol. 2026;21:103559.
PubMed

DREVET G, Kalson L, Mange L, Galateau-Salle F, et al
Moving Beyond Morphology: Toward a Morpho-Molecular Classification of Pleural Mesothelioma.
J Thorac Oncol. 2026;21:103551.
PubMed Abstract available

GUO H, Wang Y, Diao M, Han R, et al
Bispecific T-cell Engager (CD3 x EGFR)-Based Triplet Therapy Unlocks CD40/CD40L Crosstalk to Revert Immunosuppression in Third-Generation EGFR-Tyrosine Kinase Inhibitor-Refractory NSCLC.
J Thorac Oncol. 2026;21:103607.
PubMed Abstract available

April 2026

KOGA T, Ogawa H, Radulovich N, Pham NA, et al
Endobronchial Ultrasound-Guided Biopsy Derived Lung Cancer Models: A Platform for Precision Therapy.
J Thorac Oncol. 2026 Apr 27:103893. doi: 10.1016/j.jtho.2026.103893.
PubMed Abstract available

HUANG J, Chen G, Wang Z, Jin W, et al
Deulorlatinib (TGRX-326) in ALK gene fusion positive non-small cell lung cancer after failure of second-generation inhibitors (DRAGON): a single-arm, multicenter, phase 2 trial.
J Thorac Oncol. 2026 Apr 22:103737. doi: 10.1016/j.jtho.2026.103737.
PubMed Abstract available

STEWART CA, Ramkumar K, Wang R, Xi Y, et al
YAP1 defines an emergent, plastic population of relapsed small cell lung cancer.
J Thorac Oncol. 2026 Apr 20:103730. doi: 10.1016/j.jtho.2026.103730.
PubMed Abstract available

MONACA F, Gomez-Randulfe I, Torres-Jimenez J, Agarwal M, et al
Antibody-Drug Conjugates in Small-Cell Lung Cancer: DLL3, B7-H3, TROP2 and Beyond.
J Thorac Oncol. 2026 Apr 13:103726. doi: 10.1016/j.jtho.2026.103726.
PubMed Abstract available

ARDESHIR-LARINANI F, Ashrafian L, Chiappetta M, Mansilla D, et al
Challenges and Controversies in the Diagnosis and Management of Thymic Epithelial Tumors from the Thymic Tumor Subcommittee of the International Association for the Study of Lung Cancer Rare Tumors Committee.
J Thorac Oncol. 2026 Apr 10:103611. doi: 10.1016/j.jtho.2026.103611.
PubMed Abstract available

LU S, Fang J, Yu Y, Fan Y, et al
SKYSCRAPER-02C: A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of Atezolizumab Plus Carboplatin and Etoposide With or Without Tiragolumab in Patients With Untreated Extensive-Stage Small Cell Lung Cancer in China.
J Thorac Oncol. 2026 Apr 6:103713. doi: 10.1016/j.jtho.2026.103713.
PubMed Abstract available

MCMAHON RA, Lee Min Chua K, Faivre-Finn C, Filippi AR, et al
Definitive Radiotherapy to the Primary Tumor in Stage IV NSCLC: A Consensus Statement From the International Association for the Study of Lung Cancer Advanced Radiation Technology Subcommittee.
J Thorac Oncol. 2026 Apr 3:103643. doi: 10.1016/j.jtho.2026.103643.
PubMed Abstract available

LU J, Shum E, Samstein RM, Prada D, et al
Lung Cancer in Never Smokers: Genetics, Epidemiology, Environmental Exposures, and Distinct Immune Landscape.
J Thorac Oncol. 2026 Apr 1:103709. doi: 10.1016/j.jtho.2026.103709.
PubMed Abstract available

STOCKHAMMER P, El Zarif T, Schillo JL, Li F, et al
ERBB2 activating mutations and co-occurring genomic alterations contribute to disease heterogeneity in patients with ERBB2-mutant lung cancer.
J Thorac Oncol. 2026 Apr 1:103708. doi: 10.1016/j.jtho.2026.103708.
PubMed Abstract available

PUJOL JL, Milleron B, Bommart S
Screening Lung Cancer in Population-Based Real-World Programs: Searching for Efficiency Indicators.
J Thorac Oncol. 2026;21:103539.
PubMed

SALAMA JK, Mix MD, Faivre-Finn C, Bezjak A, et al
The Optimization of Radiotherapy in Lung Cancer Treatment: 20 Years of Progress.
J Thorac Oncol. 2026;21:103578.
PubMed Abstract available

ORTIZ-CUARAN S, Dupriez L, Nicq C, Lindsay CR, et al
Biology and Clinical Management of Non-V600 BRAF Alterations in NSCLC.
J Thorac Oncol. 2026;21:103531.
PubMed Abstract available

BURNS TF, Ammakkanavar NR, Hollebecque A, Lee DH, et al
Efficacy and Safety of Olomorasib in Combination With Pembrolizumab in Treatment of Patients With KRAS G12C-Mutant Advanced NSCLC.
J Thorac Oncol. 2026;21:103528.
PubMed Abstract available

SEVERSON DT, Freyaldenhoven S, Wadowski B, Hung YP, et al
Multiomic, Histologic, and scRNA-seq Profiling of Pleural Mesothelioma Reveals Negative Prognosis Associated With a Novel Uncommitted Molecular Phenotype.
J Thorac Oncol. 2026;21:103529.
PubMed Abstract available

PHAM R, Garama D, Malhotra A, Kwok A, et al
Brief Report: Alectinib With Salvage Platinum-Taxane Chemotherapy in a Pregnant Woman With ALK-Rearranged NSCLC and Rapid Disease Progression Followed by a Successful Pregnancy.
J Thorac Oncol. 2026;21:103522.
PubMed Abstract available

March 2026

PARISI C, De Giglio A, Banini M, Tagliamento M, et al
Non-Small Cell Lung Cancer (NSCLC) in Vulnerable and Special Populations: Towards Personalized Care.
J Thorac Oncol. 2026 Mar 30:103705. doi: 10.1016/j.jtho.2026.103705.
PubMed Abstract available

FUKUDA A, Fukami T, Nomura K, Kashima J, et al
Brief Report: Low Delta-like Ligand 3 expression and T Cell Exhaustion Drive Resistance to Tarlatamab combined with anti-PD-1 in Small-Cell Lung Cancer.
J Thorac Oncol. 2026 Mar 26:103693. doi: 10.1016/j.jtho.2026.103693.
PubMed Abstract available

RUSSO A, Javey M, Huang RSP, Yaung SJ, et al
Molecular Profiling across 80,000 Patients with Lung Cancer.
J Thorac Oncol. 2026 Mar 26:103695. doi: 10.1016/j.jtho.2026.103695.
PubMed Abstract available

YANG SR, Tjota MY, Goren E, Giroux DJ, et al
The International Association for the Study of Lung Cancer Pleural Mesothelioma Staging Project: Impact of Common Molecular Alterations and PD-L1 Expression on Overall Survival in a Select Cohort from the IASLC 9(th) Edition Staging Database.
J Thorac Oncol. 2026 Mar 13:103681. doi: 10.1016/j.jtho.2026.103681.
PubMed Abstract available

PONCE S, Ruiz-Torres M, Falcon A, Cote GM, et al
Combination of Lurbinectedin plus Irinotecan: Preclinical and Early Clinical Results in Relapsed Small Cell Lung Cancer Patients.
J Thorac Oncol. 2026 Mar 4:103654. doi: 10.1016/j.jtho.2026.103654.
PubMed Abstract available

TRIPHURIDET N, Ou SI
The "Inflammatory-Mutagenic" Landscape of Systemic Sclerosis (SSc)-Associated Lung Cancer: Distinct Genomics and Therapeutic Implications.
J Thorac Oncol. 2026;21:103536.
PubMed

AGRAFIOTIS AC, Rami-Porta R, Altorki N, Van Schil PE, et al
Journal of Thoracic Oncology 20th Anniversary Series Surgery.
J Thorac Oncol. 2026;21:103530.
PubMed Abstract available

RECK M, Patel JD, Gray JE, Reguart N, et al
First-Line Sacituzumab Govitecan Plus Pembrolizumab in Metastatic NSCLC: PD-L1 TPS Less Than 50% and More Than or Equal to 50% Cohorts of the EVOKE-02 Study.
J Thorac Oncol. 2026;21:103509.
PubMed Abstract available

PENG LS, Cui Q, Zhang C, Lin JT, et al
Neoadjuvant Immunochemotherapy in Resectable NSCLC With SMARCA4 Alterations.
J Thorac Oncol. 2026;21:103506.
PubMed Abstract available

CHEN MF, Lee JJ, Choudhury NJ, Hui AB, et al
Phase 2 Study of Amivantamab Plus Lazertinib in Previously Treated Patients With EGFR-Mutant Lung Cancers With Brain and Leptomeningeal Metastases.
J Thorac Oncol. 2026;21:103505.
PubMed Abstract available

ODINTSOV I, Hammer MM, Ricciuti B, Pecci F, et al
The Genomic Landscape of NSCLC in Systemic Sclerosis Reveals Frequent TP53 Mutations and a Paucity of Actionable Oncogenes.
J Thorac Oncol. 2026;21:103501.
PubMed Abstract available

ZHANG X, Wen Y, Wu F, Jiang Y, et al
GSTA1 Conferred Tolerance to Osimertinib and Provided Strategies to Overcome Drug-Tolerant Persister in EGFR-Mutant Lung Adenocarcinoma.
J Thorac Oncol. 2026;21:103494.
PubMed Abstract available

February 2026

ILLINI O, Hund AC, Kopp HG, Moskovitz M, et al
Systemic and Intracranial Efficacy and Safety of Trastuzumab Deruxtecan in Patients with HER2-Mutant Non-Small Cell Lung Cancer across Treatment Lines: Evidence from the TRACER/HERTras Real-World Cohort.
J Thorac Oncol. 2026 Feb 24:103651. doi: 10.1016/j.jtho.2026.103651.
PubMed Abstract available

GULDBRANDSEN KF, Bloch M, Skougaard K, Ahlborn LB, et al
Corrigendum to 'Surveillance With Fluorine-18 Fluorodeoxyglucose Positron Emission Tomography/Computed Tomography of Patients With Stage I-to-III Lung Cancer After Completion of Curative treatment (SUPE_R): A Randomized Controlled Trial' [Journal of T
J Thorac Oncol. 2026 Feb 24:103558. doi: 10.1016/j.jtho.2026.103558.
PubMed

ZANGHI A, Moro M, Fortunato O, Segale M, et al
Clinical Value of Combining Molecular and Immune Blood Tests to Safely Reduce False Positives in Low-Dose CT Lung Cancer Screening.
J Thorac Oncol. 2026 Feb 16:103614. doi: 10.1016/j.jtho.2026.103614.
PubMed Abstract available

ZALCMAN G, Madroszyk A, Guenzi E, Dayen C, et al
Four-Year outcomes of first-line Nivolumab plus ipilimumab for 6 months versus continuation in patients with advanced non-small-cell lung cancer Results of the randomized IFCT-1701 "DICIPLE" Phase III trial.
J Thorac Oncol. 2026 Feb 12:103609. doi: 10.1016/j.jtho.2026.103609.
PubMed Abstract available

VAN MEERBEECK JP, Bousema JE, Wen W, Van Schil PEY, et al
Staging of Lung Cancer: A Call for Developing Uniform and Universal Key Performance Indicators and Benchmarks to Elevate Clinical Standards.
J Thorac Oncol. 2026;21:253-257.
PubMed Abstract available

LAM S, Baldwin DR, Devaraj A, Field J, et al
A Game-Changing 20 Years: Progress and Future Directions in Lung Cancer Screening.
J Thorac Oncol. 2026;21:235-252.
PubMed Abstract available

AL-KHAFAJI ASK, Al-Alloosh F, Alabedi HH, Al-Obaidi KMA, et al
Lung Cancer in Iraq.
J Thorac Oncol. 2026;21:227-234.
PubMed

DI FRISCO M, Sanmamed MF, Ferrandez JM, Vilalta A, et al
Brief Report: Emphysema as a Prognostic Factor in Patients With Advanced NSCLC With COPD Receiving Immune Checkpoint Inhibitors.
J Thorac Oncol. 2026;21:328-333.
PubMed Abstract available

LE X, Baik C, Cho BC, Riess JW, et al
Osimertinib Plus Savolitinib in Patients With EGFR-Mutated Advanced NSCLC With MET Alterations After First-Line Osimertinib: Clinical Outcomes, Safety, and Biomarker Analysis: A Brief Report.
J Thorac Oncol. 2026;21:318-327.
PubMed Abstract available

MINO-KENUDSON M, Berezowska S, Minami Y, Chen S, et al
A Grading System for Resected Invasive Squamous Cell Carcinoma of the Lung: A Multi-Institutional Study by the IASLC Pathology Committee.
J Thorac Oncol. 2026;21:294-309.
PubMed Abstract available

PECCI F, Agrawal P, Ross JS, Ricciuti B, et al
Brief Report: Critical Role for DNA-Based Sequencing in Discriminating Distinct Primary Lung Cancers With Different MET Exon 14 Skipping Mutations.
J Thorac Oncol. 2026;21:310-317.
PubMed Abstract available

January 2026

NOVELLO S, Cheng Y, Spigel D, Fang J, et al
Patient-Reported Outcomes with Consolidation Durvalumab Versus Placebo Following Concurrent Chemoradiotherapy in Limited-Stage Small-Cell Lung Cancer: Results from the Phase 3 ADRIATIC Trial.
J Thorac Oncol. 2026 Jan 30:103564. doi: 10.1016/j.jtho.2026.103564.
PubMed Abstract available

MANKUZHY NP, Santo V, Shin JY, Chaunzwa TL, et al
Impact of KRAS Mutations and Co-Alterations on Outcomes in Stage III Non-Squamous Non-Small Cell Lung Cancer Treated with Chemoradiation and Immunotherapy.
J Thorac Oncol. 2026 Jan 29:103565. doi: 10.1016/j.jtho.2026.103565.
PubMed Abstract available

LEE CK, Lefresne S, Soon YY, Robledo K, et al
Osimertinib and stereotactic radiosurgery for brain metastases in EGFR mutated lung cancer - The STARLET joint analysis of OUTRUN and LUOSICNS randomised trials.
J Thorac Oncol. 2026 Jan 12:S1556-0864(26)00001.
PubMed Abstract available

HAN IS, Ko K, Zou JW, Smith AM, et al
Changes in Cardiac Function in Patients Receiving Radiation Therapy for Lung Cancer.
J Thorac Oncol. 2026 Jan 12:S1556-0864(26)00002.
PubMed Abstract available

CARBONE M, Amos C, Attanoos RL, Boeri M, et al
Advances in the Basic Sciences in Thoracic Oncology in the Last 20 Years and Their Translational Impact.
J Thorac Oncol. 2026;21:41-76.
PubMed Abstract available

WU H, Fu F, Ye T, Hu H, et al
Active Surveillance of Multifocal Ground-Glass Opacities: Results of a Prospective Multicenter Trial (ECTOP1021).
J Thorac Oncol. 2026;21:150-159.
PubMed Abstract available

KIM YW, Jung S, Kim SJ, Kang HR, et al
Trajectories of Synchronous Subsolid Nodules in Patients With Resected Subsolid Lung Adenocarcinoma: A Multicenter Cohort Study.
J Thorac Oncol. 2026;21:174-185.
PubMed Abstract available

TAKAHASHI S, Taki T, Nakamura N, Ura A, et al
Translational Analysis of NSD3 Gene Amplification in Lung Squamous Cell Carcinoma: Clinical and Prognostic Insights From Histopathologic Analysis of Patient Samples.
J Thorac Oncol. 2026;21:135-149.
PubMed Abstract available

BRUNE MM, Roma L, Chijioke O, Alborelli I, et al
MTAP Expression by Immunohistochemistry: A Novel Biomarker in NSCLC.
J Thorac Oncol. 2026;21:112-123.
PubMed Abstract available

HULBERT A, Tiv R, Cao B, Cesario D, et al
CEACAM7 Expression and DNA Methylation: Prognostic Biomarkers for Lung Adenocarcinoma in African Americans.
J Thorac Oncol. 2026;21:124-134.
PubMed Abstract available

JUANG YR, Zhao Q, Pyng L, Seow WJ, et al
REMOVED: PP01.04: Lung Cancer Risk Factors in Singapore: A Systematic Review and Meta-analysis With Comparative Insights From Across Asia.
J Thorac Oncol. 2026;21.
PubMed Abstract available

December 2025

TANIMOTO A, Ramkumar K, Stewart CA, Zhang B, et al
The impact of targeting TRAF2 and NCK-interacting protein kinase (TNIK) on anti-tumor effect and tumor immune environment in c-MYC-high small cell lung cancer.
J Thorac Oncol. 2025 Dec 26:S1556-0864(25)03066.
PubMed Abstract available

PLANCHARD D, Kim HR, Suksombooncharoen T, Li R, et al
Trastuzumab Deruxtecan in Patients with HER2-Overexpressing Non-Small Cell Lung Cancer: Results From Part 1 of the Open-label, Multicenter, Phase 1b DESTINY-Lung03 Trial.
J Thorac Oncol. 2025 Dec 23:S1556-0864(25)03021.
PubMed Abstract available

LIU Y, Li Y, Byun J, Shaw VR, et al
High penetrance rare variants underlying familial lung cancer risk: Insights from genetic epidemiology of lung cancer consortium.
J Thorac Oncol. 2025 Dec 11:S1556-0864(25)02942.
PubMed Abstract available

GOODLEY P, Balata H, Alonso A, Sharman A, et al
Population impact of risk-based lung cancer screening on late-stage incidence in Greater Manchester.
J Thorac Oncol. 2025 Dec 2:S1556-0864(25)02908.
PubMed Abstract available

FADUL MJS, Mendoza MJL, Sacdalan DBL, Samala KG, et al
Lung Cancer in the Philippines.
J Thorac Oncol. 2025;20:1747-1752.
PubMed

BOLAND JM, Lo YC, Mansfield AS
Immune Checkpoint Inhibitor Monotherapy for Patients With Pulmonary Sarcomatoid Carcinoma-The Optimal Therapeutic Strategy for This Rare Lung Cancer Subtype?
J Thorac Oncol. 2025;20:1735-1736.
PubMed

YEH YC, Chiang CH, Hsu PK, Wang LC, et al
Tumor Cell Invasion of the External Elastic Lamina Designates Visceral Pleural Invasion and Predicts Poorer Patient Outcomes in Pulmonary Nonmucinous Invasive Adenocarcinoma.
J Thorac Oncol. 2025;20:1791-1800.
PubMed Abstract available

HONG L, Di Federico A, Liu B, Cooper AJ, et al
Distinct Clinicogenomic Features and Immunotherapy Associations in Pulmonary Sarcomatoid Carcinoma: A Multicenter Retrospective Study.
J Thorac Oncol. 2025;20:1763-1777.
PubMed Abstract available

PETERS S, Schulz C, Reck M, Prabhash K, et al
Brief Report: Post Hoc Validation of Platinum Ineligibility in NSCLC From the Phase III IPSOS Study.
J Thorac Oncol. 2025;20:1843-1850.
PubMed Abstract available

November 2025

ROSS JS, Thummalapalli R, Febres-Aldana CA, Muldoon D, et al
Clinical Significance of MTAP Deletions and their Overlap with Concurrent Oncogenic Driver Alterations Including EGFR in Non-Small Cell Lung Cancer.
J Thorac Oncol. 2025 Nov 17:S1556-0864(25)02904.
PubMed Abstract available

YANG JJ, Mu Y, Wang ZH, Duan JC, et al
Andamertinib in Advanced Non-Small-Cell Lung Cancer with EGFR Exon 20 Insertions After Platinum-Based Chemotherapy or Immunotherapy: Results from the Phase 2 KANNON Study.
J Thorac Oncol. 2025 Nov 15:S1556-0864(25)02902.
PubMed Abstract available

ZHU H, Al Saifi S, Bahig H, Cooper A, et al
Radiotherapy for Unresectable Locally Advanced Non-Small Cell Lung Cancer: A Practical Multidisciplinary Approach to Challenging Scenarios from the International Association for the Study of Lung Cancer (IASLC) Advanced Radiation Technology (ART) Subc
J Thorac Oncol. 2025 Nov 14:S1556-0864(25)02899.
PubMed Abstract available

MIYAKOSHI J, Shiraishi K, Mochizuki A, Tateishi A, et al
Chromosome 15q15 Deletion Drives Brain Metastasis in Non-Small Cell Lung Cancer.
J Thorac Oncol. 2025 Nov 7:S1556-0864(25)02894.
PubMed Abstract available

CARBONE DP, Hirsch FR, Osarogiagbon RU, Nishimura KK, et al
Corrigendum to "The International Association for the Study of Lung Cancer Staging Project: The Impact of Common Molecular Alterations on Overall Survival in NSCLC in Initial Analyses of the IASLC Ninth Edition Staging Database. [Journal of Thoracic O
J Thorac Oncol. 2025 Nov 1:S1556-0864(25)02853.
PubMed

ADJEI AA
Lung Cancer in 2025: Advances in Treatment Continue, but Access Remains Unequal.
J Thorac Oncol. 2025;20:1559-1560.
PubMed

ZHOU T, Terry OC, Minton KG, Poole L, et al
Comprehensive Genomic Profiling of Rare Lung Tumors: Adenosquamous Carcinoma and Pulmonary Carcinosarcoma.
J Thorac Oncol. 2025;20:1716-1721.
PubMed Abstract available

LEE SH, Lu S, Hayashi H, Felip E, et al
Lazertinib Versus Osimertinib in Previously Untreated EGFR-Mutant Advanced NSCLC: A Randomized, Double-Blind, Exploratory Analysis From MARIPOSA.
J Thorac Oncol. 2025;20:1655-1668.
PubMed Abstract available

CARBONE M, Minaai M, Kittaneh M, Krausz T, et al
Clinical and Pathologic Phenotyping of Mesotheliomas Developing in Carriers of Germline BAP1 Mutations.
J Thorac Oncol. 2025;20:1683-1698.
PubMed Abstract available

DAGOGO-JACK I, Mitchell O, Codd E, Li A, et al
Immune Composition and Immunotherapy Outcomes of Mesothelioma With BAP1, CDKN2A, MTAP, and NF2 Alterations.
J Thorac Oncol. 2025;20:1615-1625.
PubMed Abstract available

MITSUDOMI T, Heymach JV, Reck M, Taube JM, et al
Surgical Outcomes With Neoadjuvant Durvalumab Plus Chemotherapy Followed by Adjuvant Durvalumab in Resectable NSCLC.
J Thorac Oncol. 2025;20:1639-1654.
PubMed Abstract available

AHN MJ, Lisberg A, Goto Y, Sands J, et al
A Pooled Analysis of Datopotamab Deruxtecan in Patients With EGFR-Mutated NSCLC.
J Thorac Oncol. 2025;20:1669-1682.
PubMed Abstract available

CHO H, Shiraishi K, Sunami K, Momozawa Y, et al
Genomic Profiles of Pathogenic and Moderate-Penetrance Germline Variants Associated With Risk of Early-Onset Lung Adenocarcinoma.
J Thorac Oncol. 2025;20:1626-1638.
PubMed Abstract available

October 2025

LARA-MEJIA L, Cardona AF, Mas L, Martin C, et al
Corrigendum to 'Impact of concurrent genomic alterations on clinical outcomes in patients with ALK-rearranged non-small cell lung cancer' [Journal of Thoracic Oncology, Volume 19 Issue 1 (2024) 119-129].
J Thorac Oncol. 2025 Oct 27:S1556-0864(25)02849.
PubMed

ALLGAUER M, Kluck K, Christopoulos P, Ball M, et al
Advancing Lung Cancer Staging: Integrating IASLC Recommendations and Bioinformatics to Delineate Tumor Origins.
J Thorac Oncol. 2025 Oct 22:S1556-0864(25)02857.
PubMed Abstract available

KIM SY, Silvestri GA, Park YS
A Response to Letter to the Editor: "Screening for Lung Cancer, Overdiagnosis, and Healthcare Utilization: A Nationwide Population-Based Study".
J Thorac Oncol. 2025;20:e115-e116.
PubMed

ZHAO D, Li W, Li W
Screening for Lung Cancer, Overdiagnosis, and Health Care Utilization: A Nationwide Population-Based Study.
J Thorac Oncol. 2025;20:e114-e115.
PubMed

GENDARME S, Chouaid C, Ostrin E
Comorbidities in Lung Cancer Screening: A Key to Finding the Right Spot or Opening Pandora's Box?
J Thorac Oncol. 2025;20:e112-e113.
PubMed

WU Y, Liang Y, Liang J
Exploring the Impact of Comorbidities on Lung Cancer Screening Mortality Benefits: Insights and Suggestions for Methodological Enhancement.
J Thorac Oncol. 2025;20:e111-e112.
PubMed

XIE D, Xu W
Response to the Letter to the Editor: "Recalibrating Low-Dose Computed Tomography Lung Cancer Screening: Overdiagnosis, Access, and Equity".
J Thorac Oncol. 2025;20:e104-e105.
PubMed

GAO BY, Lee YT
Recalibrating Low-Dose Computed Tomography Lung Cancer Screening: Overdiagnosis, Access, and Equity.
J Thorac Oncol. 2025;20:e103-e104.
PubMed

CHO BC, Li W, Spira AI, Sauder M, et al
Enhanced Versus Standard Dermatologic Management With Amivantamab-Lazertinib in EGFR-Mutated Advanced NSCLC: The COCOON Global Randomized Controlled Trial.
J Thorac Oncol. 2025;20:1517-1530.
PubMed Abstract available

RIELY GJ, Ahn MJ, Clarke JM, Dagogo-Jack I, et al
Updated Efficacy and Safety From the Phase 2 PHAROS Study of Encorafenib Plus Binimetinib in Patients With BRAF V600E-Mutant Metastatic NSCLC-A Brief Report.
J Thorac Oncol. 2025;20:1538-1547.
PubMed Abstract available

LEIGHL NB, Paz-Ares L, Abreu DR, Hui R, et al
LEAP-008: Lenvatinib Plus Pembrolizumab for Metastatic NSCLC That Has Progressed After an Anti-Programmed Cell Death Protein 1 or Anti-Programmed Cell Death Ligand 1 Plus Platinum Chemotherapy.
J Thorac Oncol. 2025;20:1489-1504.
PubMed Abstract available

ZHOU F, Zhang J, Ren S, Chen J, et al
Quantitative and Dynamic ctDNA as a Biomarker of Response and Survival in Patients With Advanced Lung Squamous Cell Carcinoma Receiving Immunochemotherapy or Chemotherapy Alone.
J Thorac Oncol. 2025;20:1475-1488.
PubMed Abstract available

YAO Z, Tang M, Jin Y, Ruan J, et al
Successful Pregnancy and Healthy Baby Outcome in a Patient With Tyrosine Kinase Inhibitor-Refractory ALK-Positive NSCLC and Central Nervous System Metastasis Treated With Lorlatinib With Maternal-Fetal Pharmacokinetics and Child Milestone Development
J Thorac Oncol. 2025;20:1531-1537.
PubMed Abstract available

September 2025

KIM H, Jo E, Kim J, Jang SH, et al
Screening-Detected versus Interval Lung Cancer in the Biennial Korean National Lung Cancer Screening Program: Proportion, Characteristics, and Mortality.
J Thorac Oncol. 2025 Sep 4:S1556-0864(25)01038.
PubMed Abstract available

CHEN CC, Chen SC
Cost-Efficiency of Risk-Based Lung Cancer Screening Across PLCOm2012 Risk Deciles.
J Thorac Oncol. 2025;20:e99-e100.
PubMed

RODE MM, Midthun DE
A Response to the Letter to the Editor: Cost-Efficiency of Risk-Based Lung Cancer Screening Across PLCOm2012 Risk Deciles.
J Thorac Oncol. 2025;20:e100-e101.
PubMed

LEONG TL, Steinfort DP
Broadening the Scope of Bronchoscopic Sampling in the Era of Minimally Invasive and Molecular Diagnosis of Lung Cancer.
J Thorac Oncol. 2025;20:1172-1176.
PubMed

DE GROOT P, Erasmus J, Vlahos I
Lung Cancer Screening: Future Opportunities.
J Thorac Oncol. 2025;20:1152-1155.
PubMed

PARK S, Ahn HK, Lee S, Min YJ, et al
Lazertinib for Patients with NSCLC Harboring Uncommon EGFR Mutations: A Phase II Multicenter Trial.
J Thorac Oncol. 2025;20:1279-1288.
PubMed Abstract available

August 2025

KENMOTSU H, Saito Y, Ninomiya K, Uematsu S, et al
Long-Term Safety and Effectiveness of Durvalumab in Unresectable Stage III non-small cell lung cancer in Japan: A Multicenter Prospective Study (AYAME).
J Thorac Oncol. 2025 Aug 18:S1556-0864(25)01014.
PubMed Abstract available

ENG L, Evans WK, Eisele M, Nishimura KK, et al
The International Association for the Study of Lung Cancer Staging Project: The Impact of Smoking Status on Lung Cancer Staging in the Ninth Edition of the TNM Classification.
J Thorac Oncol. 2025 Aug 4:S1556-0864(25)00824.
PubMed Abstract available

HERBST RS, Prizant H, Ruderman D, Conway J, et al
Digital Versus Manual PD-L1 Scoring in Advanced Non-Small Cell Lung Cancer From the IMpower110 and IMpower150 Trials.
J Thorac Oncol. 2025 Aug 2:S1556-0864(25)00983.
PubMed Abstract available

BANERJEE A, Vathiotis I, Halder D, Sen U, et al
Molecular Landscape and Therapeutic Strategies of Lung Cancer Lineage Plasticity.
J Thorac Oncol. 2025 Aug 2:S1556-0864(25)00773.
PubMed Abstract available

AL-RABI K, El Khatib O, Abdeljalil R, Talab Y, et al
Lung Cancer in Jordan.
J Thorac Oncol. 2025;20:1007-1017.
PubMed

NAKAZAWA S, Pecci F, Ricciuti B, Gottlieb FH, et al
Activating Mutations in the MET Kinase Domain Co-Occur With Other Driver Oncogenes and Mediate Resistance to Targeted Therapy in NSCLC.
J Thorac Oncol. 2025;20:1035-1049.
PubMed Abstract available

ZHANG B, Shah KB, Parma M, Wang K, et al
Rapid Intracranial Response With Tarlatamab in Patients With Untreated Brain Metastases From SCLC-A Real-World Case Series: Case Report.
J Thorac Oncol. 2025;20:1131-1138.
PubMed Abstract available

July 2025

JANNE PA, Goto Y, Kubo T, Ninomiya K, et al
Final analysis results and patient-reported outcomes from DESTINY-Lung02-a dose-blinded, randomized, phase 2 study of trastuzumab deruxtecan in patients with HER2-mutant metastatic non-small cell lung cancer.
J Thorac Oncol. 2025 Jul 30:S1556-0864(25)00981.
PubMed Abstract available

CARBONE DP, Hirsch FR, Osarogiagbon RU, Nishimura KK, et al
The International Association for the Study of Lung Cancer Staging Project: The Impact of Common Molecular Alterations on Overall Survival in NSCLC in Initial Analyses of the IASLC Ninth Edition Staging Database.
J Thorac Oncol. 2025 Jul 28:S1556-0864(25)00813.
PubMed Abstract available

SMELTZER MP, King JC, Connolly C, Brunson K, et al
The 2024 International Association for the Study of Lung Cancer (IASLC) Global Survey on Biomarker Testing.
J Thorac Oncol. 2025 Jul 22:S1556-0864(25)00937.
PubMed Abstract available

ALDEA M, Rotow JK, Arcila M, Hatton M, et al
Molecular Tumor Boards: A consensus statement from the International Association for the Study of Lung Cancer.
J Thorac Oncol. 2025 Jul 7:S1556-0864(25)00831.
PubMed Abstract available

NAIDOO J, Niroula A, Uprety D, Smeltzer M, et al
50 years of Progress in Non-Small Cell Lung Cancer: A New Fellow's Guide in the Clinic.
J Thorac Oncol. 2025 Jul 3:S1556-0864(25)00819.
PubMed

JIN D, Wu J, Xing W
Overdiagnosis of Lung Cancer From Low-Dose Computed Tomography Screening in Average-Risk Chinese Populations.
J Thorac Oncol. 2025;20:e89-e90.
PubMed

TAYLOR KL, Williams RM, Meza R, Smith P, et al
Reducing Lung Cancer Mortality by Providing Smoking Cessation Support in the Lung Cancer Screening Setting: Missed Opportunities and Lessons Learned on Both Sides of the Atlantic.
J Thorac Oncol. 2025;20:847-855.
PubMed Abstract available

BRUSTUGUN OT, Gronberg BH, Aanerud M, Paulsen EE, et al
Lung Cancer in Norway.
J Thorac Oncol. 2025;20:839-846.
PubMed

KILICKAP S, Baramidze A, Sezer A, Ozguroglu M, et al
Cemiplimab Monotherapy for First-Line Treatment of Patients with Advanced NSCLC With PD-L1 Expression of 50% or Higher: Five-Year Outcomes of EMPOWER-Lung 1.
J Thorac Oncol. 2025;20:941-954.
PubMed Abstract available

WU YL, Kim HR, Soo RA, Zhou Q, et al
First-Line Lorlatinib Versus Crizotinib in Asian Patients With Advanced ALK-Positive NSCLC: Five-Year Outcomes From the CROWN Study.
J Thorac Oncol. 2025;20:955-968.
PubMed Abstract available

June 2025

FUKUDA K, Nanjo S, Takeuchi S, Chakrabarti T, et al
Targeting WEE1 to overcome ARID1A mutation-driven osimertinib resistance in EGFR-mutant lung cancer.
J Thorac Oncol. 2025 Jun 13:S1556-0864(25)00766.
PubMed Abstract available

PETERS S, Regan MM, Paz-Ares LG, Reck M, et al
Treatment-Free Survival Over 6 Years of Follow-up in Patients With Metastatic Non-small Cell Lung Cancer Treated With First-Line Nivolumab Plus Ipilimumab Versus Chemotherapy in CheckMate 227 Part 1.
J Thorac Oncol. 2025 Jun 3:S1556-0864(25)00749.
PubMed Abstract available

MASCAUX C, Sen T, Sanchez-Cespedes M, Ortiz-Cuaran S, et al
Advances in lung cancer basic and translational research in 2025 - Overview and perspectives focusing on non-small cell lung cancer.
J Thorac Oncol. 2025 Jun 3:S1556-0864(25)00754.
PubMed Abstract available

TAMMEMAGI MC, Borondy-Kitts A, Field JF, Mohan A, et al
A Response to the Letter to the Editor: "Quality Performance Indicators for Lung Cancer Screening: Towards the Next Levels?".
J Thorac Oncol. 2025;20:e69-e71.
PubMed

MEERBEECK JV, Hal GV, Snoeckx A
Quality Performance Indicators for Lung Cancer Screening: Towards the Next Levels?
J Thorac Oncol. 2025;20:e68-e69.
PubMed

REVEL MP
Overcoming Barriers to Lung Cancer Screening: The Incidental Pulmonary Nodule Strategy.
J Thorac Oncol. 2025;20:705-707.
PubMed

FU F, Chen H
Bridging the Gap in Surgery for Octogenarians With Early-Stage Lung Cancer.
J Thorac Oncol. 2025;20:703-704.
PubMed

SCHEFFLER M, Wolf J, Michels S
Can Immunotherapy Be Omitted in KRAS G12C-Mutant Lung Cancer by 2025?
J Thorac Oncol. 2025;20:692-694.
PubMed

SPIRA AI, Paz-Ares L, Han JY, Shih JY, et al
Preventing Infusion-Related Reactions With Intravenous Amivantamab-Results From SKIPPirr, a Phase 2 Study: A Brief Report.
J Thorac Oncol. 2025;20:809-816.
PubMed Abstract available

MAO S, Liu X, Wang L, Wang Y, et al
AYVM to AYMM Transition on HER2 Exon 20 Insertion Induces Tyrosine Kinase Inhibitor Resistance in NSCLC.
J Thorac Oncol. 2025;20:739-749.
PubMed Abstract available

May 2025

CHADDHA U, Agrawal A, Ghori U, Kheir F, et al
Safety and Sample Adequacy for Comprehensive Biomarker Testing of Bronchoscopic Biopsies: An American Association of Bronchology and Interventional Pulmonology (AABIP) and International Association for the Study of Lung Cancer (IASLC) Clinical Practic
J Thorac Oncol. 2025 May 24:S1556-0864(25)00722.
PubMed Abstract available

HERBST RS, Cho BC, Zhou C, Burotto M, et al
Lenvatinib Plus Pembrolizumab, Pemetrexed, and a Platinum as First-Line Therapy for Metastatic Nonsquamous Non-Small-Cell Lung Cancer: Phase 3 LEAP-006 Study.
J Thorac Oncol. 2025 May 24:S1556-0864(25)00724.
PubMed Abstract available

KREBS MG, Cho BC, Hiret S, Han JY, et al
Amivantamab in Participants with Advanced Non-small Cell Lung Cancer (NSCLC) and MET Exon 14 Skipping Mutations: Final Results From the CHRYSALIS Study.
J Thorac Oncol. 2025 May 16:S1556-0864(25)00720.
PubMed Abstract available

RODE MM, Sykes AG, Allen MS, Ingalls LA, et al
Risk-Based Lung Cancer Screening in Clinical Practice.
J Thorac Oncol. 2025 May 14:S1556-0864(25)00717.
PubMed Abstract available

JONES SB, Chan C, Filippi AR, Harada K, et al
Emerging Role of Targeted Therapies Combined with Radiotherapy in Inoperable Stage I-III, Non-Small Cell Lung Cancer (NSCLC): A Review from the International Association for the Study of Lung Cancer (IASLC) Advanced Radiation Technology (ART) Subcommi
J Thorac Oncol. 2025 May 9:S1556-0864(25)00710.
PubMed Abstract available

WIESWEG M, Alaffas A, Rasokat A, Saalfeld FC, et al
Treatment sequences in BRAF-V600-mutated non-small cell lung cancer: First-line targeted therapy versus first-line (chemo-) immunotherapy.
J Thorac Oncol. 2025 May 7:S1556-0864(25)00706.
PubMed Abstract available

SABARI JK, Yu HA, Mahadevia PJ, Liu Y, et al
Overall Survival in EGFR-mutant Advanced Non-Small Cell Lung Cancer Treated with First-line Osimertinib: A Cohort Study Integrating Clinical and Biomarker Data in the United States.
J Thorac Oncol. 2025 May 2:S1556-0864(25)00699.
PubMed Abstract available

BOSTOCK I, Fox A, Engelhart K, Farjah F, et al
Response to Letter to the Editor: "Refining Surgical Decision-Making for Elderly With Lung Cancer Patients: Recognized Risks, Unmet Needs".
J Thorac Oncol. 2025;20:e63-e64.
PubMed

WANG F, Bao M, Zhu L
Refining Surgical Decision-Making for Elderly Patients With Lung Cancer: Recognized Risks, Unmet Needs.
J Thorac Oncol. 2025;20:e62-e63.
PubMed

MREMI A, Ndumbalo J, Chuwa H, Henke O, et al
Lung Cancer in Tanzania.
J Thorac Oncol. 2025;20:560-564.
PubMed

DE-TORRES JP, Varo N
The Tree That Let Us See the Forest: The Importance of Comorbidities in Lung Cancer Screening Programs.
J Thorac Oncol. 2025;20:555-556.
PubMed

YANAGISAWA A, Shiroyama T, Miyake K, Takeda Y, et al
Diabetic Ketoacidosis During Lorlatinib Treatment: Case Report.
J Thorac Oncol. 2025;20:676-679.
PubMed Abstract available

LINDBERG A, Muhl L, Yu H, Hellberg L, et al
In Situ Detection of Programmed Cell Death Protein 1 and Programmed Death Ligand 1 Interactions as a Functional Predictor for Response to Immune Checkpoint Inhibition in NSCLC.
J Thorac Oncol. 2025;20:625-640.
PubMed Abstract available

April 2025

GRONBERG BH, Killingberg KT, Flotten O, Bjaanaes MM, et al
High-dose versus standard dose twice-daily thoracic radiotherapy in limited stage small-cell lung cancer: final survival data, long-term toxicity and relapse patterns in a randomised, open-label, phase II trial.
J Thorac Oncol. 2025 Apr 19:S1556-0864(25)00696.
PubMed Abstract available

GULDBRANDSEN KF, Bloch M, Skougaard K, Ahlborn LB, et al
Surveillance with [(18)F]FDG PET/CT of stage I-III lung cancer patients after completion of curative treatment (SUPE_R): a randomized controlled trial.
J Thorac Oncol. 2025 Apr 19:S1556-0864(25)00693.
PubMed Abstract available

HAMADA A, Soh J, Hata A, Nakamatsu K, et al
Neoadjuvant Concurrent Chemo-immuno-radiation Therapy Followed by Surgery and Adjuvant Immunotherapy for Resectable Stage III N2 Non-Small Cell Lung Cancer: Primary Results from SQUAT trial (WJOG 12119L).
J Thorac Oncol. 2025 Apr 9:S1556-0864(25)00656.
PubMed Abstract available

BOERI M, Zanghi A, Pastorino U
New Horizons in Lung Cancer Screening: Eligibility Criteria, Risk Models, and Emerging Challenges.
J Thorac Oncol. 2025;20:422-424.
PubMed

KIM YW, Lee CT
Advancing the Implementation of Risk Model-Based Lung Cancer Screening.
J Thorac Oncol. 2025;20:419-421.
PubMed

PARIKH K, Hashmi A, Chauhan PS, Chaudhuri AA, et al
Plasma-First Testing in Advanced Lung Cancer: Evidence and Implications.
J Thorac Oncol. 2025;20:411-414.
PubMed

XIA Y, Wang K, Zhao J, Arter Z, et al
Receptor Tyrosine Kinase Fusion-Mediated Resistance to EGFR TKI in EGFR-Mutant NSCLC: A Multi-Center Analysis and Literature Review.
J Thorac Oncol. 2025;20:465-474.
PubMed Abstract available

NAKAGAWA K, Garon EB, Seto T, Nishio M, et al
RELAY: Final Overall Survival for Erlotinib Plus Ramucirumab or Placebo in Untreated, EGFR-Mutated Metastatic NSCLC.
J Thorac Oncol. 2025;20:487-499.
PubMed Abstract available

BLECHTER B, Hsiung CA, Wang X, Zhang H, et al
Polygenic Risk Score and Lung Adenocarcinoma Risk Among Never-Smokers by EGFR Mutation Status: A Brief Report.
J Thorac Oncol. 2025;20:521-530.
PubMed Abstract available

LEUNISSEN DJG, Moonen L, von der Thusen JH, den Bakker MA, et al
Identification of Defined Molecular Subgroups on the Basis of Immunohistochemical Analyses and Potential Therapeutic Vulnerabilities of Pulmonary Carcinoids.
J Thorac Oncol. 2025;20:451-464.
PubMed Abstract available

March 2025

SEDER CW, Chang SC, Towe CW, Puri V, et al
Anatomic Lung Resection is Associated with Improved Survival Compared with Wedge Resection for Stage IA (
J Thorac Oncol. 2025 Mar 23:S1556-0864(25)00641.
PubMed Abstract available

HAKOZAKI T, Tanaka K, Shiraishi Y, Sekino Y, et al
Gut Microbiota in Advanced Non-small-cell Lung Cancer Receiving Chemo-immunotherapy: An Ancillary Biomarker Study from the Phase III trial JCOG2007 (NIPPON).
J Thorac Oncol. 2025 Mar 7:S1556-0864(25)00106.
PubMed Abstract available

CHEN P, Wang H, Tang Z, Shi J, et al
Selective depletion of CCR8+Treg cells enhances anti-tumor immunity of cytotoxic T cells in lung cancer via dendritic cells.
J Thorac Oncol. 2025 Mar 6:S1556-0864(25)00109.
PubMed Abstract available

BROWN M, Myers R, Lam S
Enlarging the Reach of Screening and Early Detection of Lung Cancer.
J Thorac Oncol. 2025;20:249-251.
PubMed

CHOU TY, Dacic S, Wistuba I, Beasley MB, et al
Differentiating Separate Primary Lung Adenocarcinomas From Intrapulmonary Metastases With Emphasis on Pathological and Molecular Considerations: Recommendations From the International Association for the Study of Lung Cancer Pathology Committee.
J Thorac Oncol. 2025;20:311-330.
PubMed Abstract available

LU S, Wu L, Wang Q, Wang Z, et al
Durvalumab Versus Chemotherapy as First-line Treatment for Metastatic NSCLC With Tumor PD-L1 Expression of 25% or Higher: Results From the Randomized Phase 3 PEARL Study.
J Thorac Oncol. 2025;20:366-382.
PubMed Abstract available

MARINELLI D, Nuccio A, Di Federico A, Ambrosi F, et al
Improved Event-Free Survival After Complete or Major Pathologic Response in Patients With Resectable NSCLC Treated With Neoadjuvant Chemoimmunotherapy Regardless of Adjuvant Treatment: A Systematic Review and Individual Patient Data Meta-Analysis.
J Thorac Oncol. 2025;20:285-295.
PubMed Abstract available

February 2025

XIE D, Zhang L, He N, Yang C, et al
Overdiagnosis of Lung Cancer due to Introduction of Low-Dose Computed Tomography in Average-Risk Populations in China.
J Thorac Oncol. 2025 Feb 13:S1556-0864(25)00072.
PubMed Abstract available

CALLES A, Navarro A, Doger Speville Uribe BG, Alvarez Colome E, et al
Lurbinectedin plus pembrolizumab in relapsed small cell lung cancer (SCLC): the phase I/II LUPER study.
J Thorac Oncol. 2025 Feb 10:S1556-0864(25)00064.
PubMed Abstract available

FONG KM, Rosenthal A, Giroux DJ, Nishimura KK, et al
Corrigendum to 'The International Association for the Study of Lung Cancer Staging Project for Lung Cancer: Proposals for the Revision of the M Descriptors in the Forthcoming Ninth Edition of the TNM Classification for Lung Cancer' [Journal of Thoraci
J Thorac Oncol. 2025 Feb 9:S1556-0864(25)00050.
PubMed

HAN B, Liu J, Wu L, Zhao Y, et al
Safety, Pharmacokinetics, and Efficacy of TY-9591 (Deuterated Osimertinib Derivative) in Advanced EGFR-mutated Non-Small Cell Lung Cancer: A Phase 1 Dose-Escalation and Dose-Expansion Study.
J Thorac Oncol. 2025 Feb 8:S1556-0864(25)00062.
PubMed Abstract available

LI YS, Yu Q, Bu Q, Lin L, et al
First-Line Camrelizumab versus Placebo Plus Chemotherapy with or without Radiotherapy for Brain Metastases in Non-Small-Cell Lung Cancer: The CTONG 2003 Randomized Placebo-Controlled Trial.
J Thorac Oncol. 2025 Feb 8:S1556-0864(25)00063.
PubMed Abstract available

ABBAR B, Labreche K, Cadranel J, Veyri M, et al
HIV Impairs Immune Responses to Tumor Neoepitopes Without Altering Mutational Profiles in Non-Small Cell Lung Cancer.
J Thorac Oncol. 2025 Feb 7:S1556-0864(25)00060.
PubMed Abstract available

SILVESTRI GA, Young R, Tanner NT, Mazzone P, et al
A Response to the Letter to the Editor: "Failure to Include Nonsmokers in Computed Tomography Screening for Lung Cancer is Unjust".
J Thorac Oncol. 2025;20:e39-e40.
PubMed

SILVESTRI GA, Young R, Tanner NT, Mazzone P, et al
A Response to the Letter to the Editor: "Lung Cancer Screening in Low-Risk Populations: Ethical Considerations, Technological Advancements, and Socioeconomic Challenges".
J Thorac Oncol. 2025;20:e36-e37.
PubMed

LI J, Zhang Y, Fu T, Tong Y, et al
Lung Cancer Screening in Low-Risk Populations: Ethical Considerations, Technological Advancements, and Socioeconomic Challenges.
J Thorac Oncol. 2025;20:e35-e36.
PubMed

SILVESTRI GA, Young R, Tanner NT, Mazzone P, et al
A Response to the Letter to the Editor: "Secondhand Smoke in Low-Risk Groups: A Hidden Danger in Lung Cancer Screening".
J Thorac Oncol. 2025;20:e34.
PubMed

CUI Y
Secondhand Smoke in Low-Risk Groups: A Hidden Danger in Lung Cancer Screening.
J Thorac Oncol. 2025;20:e33-e34.
PubMed

RIZZO MM, Barros M, Chimondeguy D, Dalurzo ML, et al
Lung Cancer in Argentina.
J Thorac Oncol. 2025;20:144-149.
PubMed

BAK M, Park H, Lee SH, Lee N, et al
The Risk and Reversibility of Osimertinib-Related Cardiotoxicity in a Real-World Population.
J Thorac Oncol. 2025;20:167-176.
PubMed Abstract available

NAKAGAWA K, Watanabe SI, Wakabayashi M, Yotsukura M, et al
Risk Factors for Locoregional Relapse After Segmentectomy: Supplementary Analysis of the JCOG0802/WJOG4607L Trial.
J Thorac Oncol. 2025;20:157-166.
PubMed Abstract available

LEE J, Jeon JH, Chung JH, Son JW, et al
Prognostic Impact of Non-Predominant Lepidic Components in Pathologic Stage I Invasive Nonmucinous Adenocarcinoma.
J Thorac Oncol. 2025;20:194-202.
PubMed Abstract available

January 2025

LIAO W, Ray MA, Patel A, Roma J, et al
Barriers to Lung Cancer Screening in a Multi-Disciplinary Thoracic Oncology Program Cohort: Effects of an Incidental Pulmonary Nodule Program.
J Thorac Oncol. 2025 Jan 30:S1556-0864(25)00057.
PubMed Abstract available

BOSTOCK IC, Fox AH, Ward RC, Engelhardt KE, et al
Outcomes After Surgical Management of Early-Stage Lung Cancer in Octogenarians: An in-depth Analysis of a Nationally Representative Cohort.
J Thorac Oncol. 2025 Jan 28:S1556-0864(25)00053.
PubMed Abstract available

TAMMEMAGI MC, Borondy-Kitts A, Field JK, Henschke CI, et al
Lung cancer screening program quality indicators - review & recommendations - An International Association for the Study of Lung Cancer Delphi process study.
J Thorac Oncol. 2025 Jan 24:S1556-0864(25)00052.
PubMed Abstract available

GANDHI MM, Elkrief A, Moore CG, Ricciuti B, et al
Gene copy deletion of STK11, KEAP1, and SMARCA4: clinicopathologic features and association with outcomes to immunotherapy +/- chemotherapy in nonsquamous non-small cell lung cancer.
J Thorac Oncol. 2025 Jan 24:S1556-0864(25)00049.
PubMed Abstract available

TSAO MS, Rosenthal A, Nicholson AG, Detterbeck F, et al
The International Association for the Study of Lung Cancer Staging Project: The Database and Proposal for the Revision of the Staging of Pulmonary Neuroendocrine Carcinoma in the Forthcoming Ninth Edition of the TNM Classification for Lung Cancer.
J Thorac Oncol. 2025 Jan 24:S1556-0864(25)00046.
PubMed Abstract available

AKAMATSU H, Sakata S, Azuma K, Yoshioka H, et al
A single-arm, phase II study of sotorasib plus carboplatin/pemetrexed in advanced non-squamous non-small cell lung cancer patients with KRAS G12C mutation (WJOG14821L, SCARLET).
J Thorac Oncol. 2025 Jan 17:S1556-0864(25)00007.
PubMed Abstract available

GENDARME S, Irajizad E, Long JP, Fahrmann JF, et al
Impact of comorbidities on the mortality benefits of lung cancer screening: a post-hoc analysis of PLCO and NLST trials.
J Thorac Oncol. 2025 Jan 9:S1556-0864(25)00004.
PubMed Abstract available

BESSE B, Goto K, Wang Y, Lee SH, et al
Amivantamab Plus Lazertinib in Patients With EGFR-mutant Non-small Cell Lung Cancer (NSCLC) After Progression on Osimertinib and Platinum-based Chemotherapy: Results From CHRYSALIS-2 Cohort A.
J Thorac Oncol. 2025 Jan 2:S1556-0864(24)02550.
PubMed Abstract available

FUKUI T, Mamesaya N, Takahashi T, Kishi K, et al
A Prospective Phase II Trial of First-line Osimertinib for Patients with EGFR Mutation-positive Non-small Cell Lung Cancer and Poor Performance Status (OPEN/TORG2040).
J Thorac Oncol. 2025 Jan 2:S1556-0864(24)02548.
PubMed Abstract available

DOWLATI A, Chiang AC, Cervantes A, Babu S, et al
Phase 2 Open-Label Study of Sacituzumab Govitecan as Second-Line Therapy in Patients With Extensive-Stage Small Cell Lung Cancer: Results From TROPiCS-03.
J Thorac Oncol. 2025 Jan 2:S1556-0864(24)02549.
PubMed Abstract available

HUBER RM, Lam S, Cavic M, Balata H, et al
Response to the Letters to the Editor by Jing Peng and Colleagues and by Lauren C Leiman Regarding the Manuscript "Terminology Issues in Screening and Early Detection of Lung Cancer-International Association for the Study of Lung Cancer Early Detectio
J Thorac Oncol. 2025;20:e6-e8.
PubMed

PENG J, Zhao L, Shan D
Enhancing Clinical Precision and Patient Communication in Lung Cancer Screening.
J Thorac Oncol. 2025;20:e3-e4.
PubMed

GADGEEL SM, Jensen E, Shamoun M, Rajagopalan K, et al
Response to: Enhancing Clinical Practice: Critical Insights for Medical Workers in Applying Pembrolizumab for Metastatic NSCLC and Pembrolizumab, Chemotherapy and Metastatic Non-Small Cell Lung Cancer.
J Thorac Oncol. 2025;20:e11-e12.
PubMed

BORGHAEI H, Mok T
Leptomeningeal Disease in Lung Cancer: An Unmet Need That Needs to Be Met.
J Thorac Oncol. 2025;20:17-19.
PubMed

LI HJ, Qiu ZB, Wang MM, Zhang C, et al
Radiomics-Based Support Vector Machine Distinguishes Molecular Events Driving the Progression of Lung Adenocarcinoma.
J Thorac Oncol. 2025;20:52-64.
PubMed Abstract available

PETERS S, Cho BC, Luft AV, Alatorre-Alexander J, et al
Durvalumab With or Without Tremelimumab in Combination With Chemotherapy in First-Line Metastatic NSCLC: Five-Year Overall Survival Outcomes From the Phase 3 POSEIDON Trial.
J Thorac Oncol. 2025;20:76-93.
PubMed Abstract available

December 2024

WARKENTIN MT, Tammemagi MC, Vakil E, Bedard ELR, et al
Brief Report: Evaluating Early-Stage Lung Cancer Survival Patterns in Patients at the Upper Age Limit for Lung Cancer Screening.
J Thorac Oncol. 2024 Dec 30:S1556-0864(24)02546.
PubMed Abstract available

LEE JB, Choi SJ, Shim HS, Park BJ, et al
Neoadjuvant and adjuvant osimertinib in stage IA-IIIA, EGFR-mutant non-small cell lung cancer (NORA).
J Thorac Oncol. 2024 Dec 26:S1556-0864(24)02544.
PubMed Abstract available

GABE R, Crosbie PAJ, Vulkan D, Bailey H, et al
Prospective evaluation of lung cancer screening eligibility criteria and lung cancer detection in the Yorkshire Lung Screening Trial.
J Thorac Oncol. 2024 Dec 19:S1556-0864(24)02535.
PubMed Abstract available

PASSIGLIA F, Listi A, Bironzo P, Merlini A, et al
Actionable non-small cell lung cancer mutation identification by comprehensive genomic profiling for clinical trial enrollment: the European Program for the ROutine testing of Patients with Advanced lung cancer (EPROPA).
J Thorac Oncol. 2024 Dec 16:S1556-0864(24)02529.
PubMed Abstract available

SWALDUZ A, Schiffler C, Curcio H, Ambasager B, et al
LIBELULE: a randomized phase III study to evaluate the clinical relevance of early liquid biopsy in patients with suspicious metastatic lung cancer.
J Thorac Oncol. 2024 Dec 16:S1556-0864(24)02530.
PubMed Abstract available

TAVERNARI D, Borgeaud M, Liu X, Kaushal P, et al
Decoding the Clinical and Molecular Signatures of EGFR Common, Compound, and Uncommon Mutations in Non-Small Cell Lung Cancer.
J Thorac Oncol. 2024 Dec 16:S1556-0864(24)02531.
PubMed Abstract available

HOFFMANN H, Nicholson AG, Detterbeck FC, Tsao MS, et al
The International Association for the Study of Lung Cancer Lung Cancer Staging Project: Application and Interpretation of the Residual Tumor (R) Classification for Lung Cancer. Results from an International Survey among Pathologists and Thoracic Surge
J Thorac Oncol. 2024 Dec 13:S1556-0864(24)02526.
PubMed Abstract available

KIM SY, Silvestri GA, Kim YW, Kim RY, et al
Screening for Lung Cancer, Overdiagnosis, and Healthcare Utilization: A Nationwide Population-Based Study.
J Thorac Oncol. 2024 Dec 9:S1556-0864(24)02503.
PubMed Abstract available

PHILLIPS WJ, Watson AS, Camidge DR
The use of investigator-assigned subjective or judgmental efficacy and toxicity reporting in early phase clinical trials of lung cancer treatments.
J Thorac Oncol. 2024 Dec 4:S1556-0864(24)02498.
PubMed Abstract available

XU X, Xie J, Luo Z
Strengthening the Evidence: Expanding Research on Passive Smoking and Lung Cancer.
J Thorac Oncol. 2024;19:e94-e95.
PubMed

LI Z, Liu J, Liu H, Wu C, et al
Comment on "A Real-World Assessment of Stage I Lung Cancer Through Electronic Nose Technology".
J Thorac Oncol. 2024;19:e89-e90.
PubMed

ZHOU RX, Ye DW
Reply to the Letter to the Editor: The Relationship Between Air Pollution and Lung Cancer: Differences in Sensitivity Across Regions and Populations.
J Thorac Oncol. 2024;19:e82-e84.
PubMed

WANG L, Wang Z, Wang G
The Relationship Between Air Pollution and Lung Cancer: Differences in Sensitivity Across Regions and Populations.
J Thorac Oncol. 2024;19:e81-e82.
PubMed

JENSEN SO, Moore DA, Surani AA, Crosbie PAJ, et al
Second Primary Lung Cancer-Potential Areas of Ambiguity.
J Thorac Oncol. 2024;19:e101-e102.
PubMed

NIU Y, Xie J, Li Z
Second Primary Lung Cancer-Potential Areas of Ambiguity.
J Thorac Oncol. 2024;19:e100-e101.
PubMed

GUISSEVE A, Mualinque A, Cossa M, Jerez AD, et al
Lung Cancer in Mozambique.
J Thorac Oncol. 2024;19:1599-1605.
PubMed

TONG BC, Stinchcombe TE
Lung Cancer Screening and Early Detection Terminology: Time to Sing From the Same Song Sheet.
J Thorac Oncol. 2024;19:1589-1590.
PubMed

KOZONO D, Hua X, Wu MC, Tolba KA, et al
Lung-MAP Next-Generation Sequencing Analysis of Advanced Squamous Cell Lung Cancers (SWOG S1400).
J Thorac Oncol. 2024;19:1618-1629.
PubMed Abstract available

November 2024

HEERSCHE N, Lanser DAC, Muntinghe-Wagenaar MB, Mohmaed Ali MI, et al
Sex and common germline variants impact the toxicity profile and pharmacokinetics of alectinib: a nation-wide cohort study in patients with ALK-positive non-small cell lung cancer.
J Thorac Oncol. 2024 Nov 29:S1556-0864(24)02488.
PubMed Abstract available

KAZI A, Kantilal Vasiyani HK, Ghosh D, Bandyopadhyay D, et al
FGTI-2734 Inhibits ERK Reactivation to Overcome Sotorasib Resistance in KRAS G12C Lung Cancer.
J Thorac Oncol. 2024 Nov 25:S1556-0864(24)02485.
PubMed Abstract available

IGNATIUS OU SH, Solomon BJ, Besse B, Bearz A, et al
Brief Report: Final overall survival and long-term safety of lorlatinib in patients with ALK-positive non-small cell lung cancer from the pivotal phase 2 study.
J Thorac Oncol. 2024 Nov 22:S1556-0864(24)02484.
PubMed Abstract available

DAMARAJU V, Krushna Karri JK, Gandrakota G, Marimuthu Y, et al
Low dose computed tomography for lung cancer screening in Tuberculosis endemic countries: A Systematic Review and Meta-analysis.
J Thorac Oncol. 2024 Nov 22:S1556-0864(24)02483.
PubMed Abstract available

LEVY A, Rusthoven CG, Brown PD, Le Pechoux C, et al
PCI for Patients with Small Cell Lung Cancer: A New Perspective in the Immunotherapy Era.
J Thorac Oncol. 2024 Nov 15:S1556-0864(24)02446.
PubMed Abstract available

ZHAO S, Zhou H, Yang N, Wang Z, et al
Safety, efficacy and biomarker analysis of deulorlatinib (TGRX-326) in ALK-positive non-small-cell lung cancer: a multicentre, open-label, phase 1/1b trial.
J Thorac Oncol. 2024 Nov 15:S1556-0864(24)02445.
PubMed Abstract available

TUMINELLO S, Flores R, Untalan M, Ivic-Pavlicic T, et al
Predicted effect of incidental pulmonary nodule findings on Non-Small Cell Lung Cancer mortality.
J Thorac Oncol. 2024 Nov 12:S1556-0864(24)02444.
PubMed Abstract available

ECHEPARE M, Picabea B, Arricibita A, Teijeira A, et al
DSTYK Inhibition Sensitizes Non-Small Cell Lung Cancer To Taxane-Based Chemotherapy.
J Thorac Oncol. 2024 Nov 11:S1556-0864(24)02438.
PubMed Abstract available

GRAY JE, Schenker M, Nahit Sendur MA, Leonova V, et al
The Phase 3 KEYLYNK-006 Study of Pembrolizumab plus Olaparib versus Pembrolizumab plus Pemetrexed as Maintenance Therapy for Metastatic Nonsquamous Non-Small-Cell Lung Cancer.
J Thorac Oncol. 2024 Nov 7:S1556-0864(24)02435.
PubMed Abstract available

KARIM NA, Miao J, Reckamp KL, Gay CM, et al
Phase II randomized study of maintenance atezolizumab (A) versus atezolizumab + talazoparib (AT) in patients with SLFN11 positive extensive stage small cell lung cancer. S1929.
J Thorac Oncol. 2024 Nov 4:S1556-0864(24)02431.
PubMed Abstract available

OLTEANU GE, Vigdorovits A, Barna RA, Mazilu L, et al
Lung Cancer in Romania.
J Thorac Oncol. 2024;19:1492-1503.
PubMed

D'AMOURS MF, Hughesman CB, Yip ST, Ho C, et al
The Game is Afoot - Seeking Early-Stage Lung Cancer Circulating Tumor DNA.
J Thorac Oncol. 2024;19:1479-1481.
PubMed

ADJEI AA
How Can We Conquer Lung Cancer?
J Thorac Oncol. 2024;19:1477-1478.
PubMed

KINDLER HL, Rosenthal A, Giroux DJ, Nowak AK, et al
The International Association for the Study of Lung Cancer Mesothelioma Staging Project: Proposals for the M Descriptors in the Forthcoming Ninth Edition of the TNM Classification for Pleural Mesothelioma.
J Thorac Oncol. 2024;19:1564-1577.
PubMed Abstract available

PARIKH K, Dimou A, Leventakos K, Mansfield AS, et al
Impact of EML4-ALK Variants and Co-Occurring TP53 Mutations on Duration of First-Line ALK Tyrosine Kinase Inhibitor Treatment and Overall Survival in ALK Fusion-Positive NSCLC: Real-World Outcomes From the GuardantINFORM database.
J Thorac Oncol. 2024;19:1539-1549.
PubMed Abstract available

HONG TH, Hwang S, Dasgupta A, Abbosh C, et al
Clinical Utility of Tumor-Naive Presurgical Circulating Tumor DNA Detection in Early-Stage NSCLC.
J Thorac Oncol. 2024;19:1512-1524.
PubMed Abstract available

October 2024

HOCHMAIR M, Schenker M, Dols MC, Kim TM, et al
Pembrolizumab With or Without Maintenance Olaparib for Metastatic Squamous Non-Small-Cell Lung Cancer That Responded to First-Line Pembrolizumab Plus Chemotherapy.
J Thorac Oncol. 2024 Oct 28:S1556-0864(24)02420.
PubMed Abstract available

CHEN Z, Wu L, Wang Q, Yu Y, et al
Brief report: Ivonescimab combined with etoposide plus carboplatin as first-line treatment for extensive-stage small-cell lung cancer: results of a phase Ib clinical trial.
J Thorac Oncol. 2024 Oct 26:S1556-0864(24)02421.
PubMed Abstract available

UMEMURA S, Udagawa H, Ikeda T, Murakami H, et al
Clinical significance of a prospective large genomic screening for small-cell lung cancer: the genetic classification and a biomarker driven phase II trial of gedatolisib.
J Thorac Oncol. 2024 Oct 10:S1556-0864(24)02378.
PubMed Abstract available

PETERS S, Paz-Ares LG, Reck M, Carbone DP, et al
Long-Term Survival Outcomes With First-Line Nivolumab Plus Ipilimumab-Based Treatment in Patients With Metastatic Non-Small Cell Lung Cancer and Tumor PD-L1 <1%: a Pooled Analysis.
J Thorac Oncol. 2024 Oct 4:S1556-0864(24)02355.
PubMed Abstract available

LEVY A, Adebahr S, Hurkmans C, Fortpied C, et al
A Response to the Letter to the Editor: "Comment on Stereotactic Body Radiotherapy for Centrally Located Inoperable Early Stage NSCLC: EORTC 22113-08113 LungTech Phase II Trial Results".
J Thorac Oncol. 2024;19:e57-e59.
PubMed

XU Z, Jiang J, Guo H, Zhao D, et al
Comment on "Stereotactic Body Radiotherapy for Centrally Located Inoperable Early-Stage NSCLC: EORTC 22113-08113 LungTech Phase II Trial Results".
J Thorac Oncol. 2024;19:e56-e57.
PubMed

RAMI-PORTA R, Call S, Sanz-Santos J
Reply to "Impact of the Ninth IASLC TNM Classification on Endobronchial Ultrasound for Lung Cancer Staging" by Faria et al.
J Thorac Oncol. 2024;19:e55-e56.
PubMed

FARIA N, Costa MI, Lacerda C, Sucena M, et al
Impact of the Ninth International Association for the Study of Lung Cancer TNM Classification on Endobronchial Ultrasound for Lung Cancer Staging.
J Thorac Oncol. 2024;19:e53-e55.
PubMed

KOHNO T, Mochizuki A
Response to Letter to the Editor.
J Thorac Oncol. 2024;19:e52-e53.
PubMed

GU X, Han Z, Shi W
Comment on "Passive Smoking-Induced Mutagenesis as a Promoter of Lung Carcinogenesis".
J Thorac Oncol. 2024;19:e51-e52.
PubMed

ZHUANG WT, Hu LY, Fang WF
Response to Commentary on "EGFR Oncogenic Mutations in NSCLC Impair Macrophage Phagocytosis and Mediate Innate Immune Evasion Through Up-Regulation of CD47".
J Thorac Oncol. 2024;19:e50-e51.
PubMed

PAN Y
Comment on "EGFR Oncogenic Mutations in NSCLC Impair Macrophage Phagocytosis and Mediate Innate Immune Evasion Through Up-Regulation of CD47".
J Thorac Oncol. 2024;19:e49-e50.
PubMed

SHI Y
A Response to the Letter to the Editor: Response to Ficonalkib's Promise and the Path Forward: A Comment on Advanced ALK-Positive NSCLC Treatment.
J Thorac Oncol. 2024;19:e48.
PubMed

GE MW, Chen HL
Ficonalkib's Promise and the Path Forward: A Comment on Advanced ALK-Positive NSCLC Treatment.
J Thorac Oncol. 2024;19:e47-e48.
PubMed

CABALLE-PEREZ E, Cabrera-Miranda L, Arrieta O
Exploring EGFR Mutations in Resected Stage I-III NSCLC in Low- and Middle-Income Countries: Bridging the Gap in Global Cancer Care.
J Thorac Oncol. 2024;19:1367-1369.
PubMed

PUJOL JL, Erich Eberhardt WE
Familial Lung Cancers Caused by EGFR Germline Mutations: The Frequency Is Probably Underestimated but Specific Genotypic Features and Some Particular Disease Characteristics Should Help Their Screening.
J Thorac Oncol. 2024;19:1364-1366.
PubMed

SOO RA, Reungwetwattana T, Perroud HA, Batra U, et al
Prevalence of EGFR Mutations in Patients With Resected Stages I to III NSCLC: Results From the EARLY-EGFR Study.
J Thorac Oncol. 2024;19:1449-1459.
PubMed Abstract available

PAN K, Owens J, Elamin Y, Lu C, et al
Mutational Characteristics and Clinical Outcomes for Lung Adenocarcinoma With EGFR Germline Mutations.
J Thorac Oncol. 2024;19:1438-1448.
PubMed Abstract available

BUROTTO M, Zvirbule Z, Alvarez R, Chewaskulyong B, et al
Brief Report: Updated Data From IMscin001 Part 2, a Randomized Phase III Study of Subcutaneous Versus Intravenous Atezolizumab in Patients With Locally Advanced or Metastatic NSCLC.
J Thorac Oncol. 2024;19:1460-1466.
PubMed Abstract available

September 2024

SAID BI, Geng Y, Badiyan SN, Bang A, et al
Accelerated hypofractionated radiotherapy for locally-advanced non-small cell lung cancer: A systematic review from the International Association for the Study of Lung Cancer (IASLC) Advanced Radiation Technology (ART) Subcommittee.
J Thorac Oncol. 2024 Sep 28:S1556-0864(24)02353.
PubMed Abstract available

PARK HS, Rimner A, Amini A, Chang JY, et al
Executive Summary of the American Radium Society(R) (ARS) Appropriate Use Criteria (AUC) for Non-Small Cell Lung Cancer in a Central/Ultra-Central Location: Systematic Review and Guidelines.
J Thorac Oncol. 2024 Sep 11:S1556-0864(24)02268.
PubMed Abstract available

NASSAR AH, Jayakrishnan R, Feng J, Shepherd F, et al
Consolidation ALK Tyrosine Kinase Inhibitors versus Durvalumab or Observation After Chemoradiation in Unresectable Stage III ALK+ Non-Small Cell Lung Cancer.
J Thorac Oncol. 2024 Sep 9:S1556-0864(24)02265.
PubMed Abstract available

CHEN H, Yang S, Wang L, Wu Y, et al
High-dose Furmonertinib in patients with EGFR-mutated non-small cell lung cancer and leptomeningeal metastases: A prospective real-world study.
J Thorac Oncol. 2024 Sep 9:S1556-0864(24)02269.
PubMed Abstract available

HORNE A, Harada K, Brown KD, Lee Min Chua K, et al
Erratum to "Treatment response biomarkers: working towards personalised radiotherapy for lung cancer. [Journal of Thoracic Oncology Vol. 19 No. 8: 1164-1185]".
J Thorac Oncol. 2024 Sep 5:S1556-0864(24)00775.
PubMed

ERNST SM, von der Thusen JH, Dubbink HJ, Dingemans AC, et al
A Response to the Letter to the Editor: Comment on "Clinical Utility of Circulating Tumor DNA in Patients With Advanced KRAS(G12C)-Mutated NSCLC Treated With Sotorasib".
J Thorac Oncol. 2024;19:e44-e45.
PubMed

JIANG Y, Zhang L
Comment on "Clinical Utility of Circulating Tumor DNA in Patients With Advanced KRAS(G12C)-Mutated NSCLC Treated With Sotorasib".
J Thorac Oncol. 2024;19:e43.
PubMed

LEVY A, Adebahr S, Hurkmans C, Fortpied C, et al
A Response to the Letter to the Editor: The Role of Personalization and Standardization in Stereotactic Body Radiation Therapy.
J Thorac Oncol. 2024;19:e41-e43.
PubMed

ROMA L, Bubendorf L
Suggestions for Improving the Comprehensive Characterization of Lung Pleomorphic Carcinoma.
J Thorac Oncol. 2024;19:e38-e39.
PubMed

ZHOU L, Li M, Li W
Suggestions for Improving the Comprehensive Characterization of Lung Pleomorphic Carcinoma.
J Thorac Oncol. 2024;19:e37-e38.
PubMed

TUMINELLO S, Gulati S, Ivic-Pavlicic T, Flores R, et al
Response to: "The Value of Incidental Imaging for Early Stage Lung Cancer in High-Risk Nonscreening Cohort: Some Additional Considerations?".
J Thorac Oncol. 2024;19:e36.
PubMed

NIU Y, Xie J, Li Z
The Value of Incidental Imaging for Early-Stage Lung Cancer in a High-Risk Non-Screening Cohort: Some Additional Considerations?
J Thorac Oncol. 2024;19:e34-e35.
PubMed

HIGASHIYAMA RI, Yoshida T
A Response to the Letter to the Editor: Safety Implications of Switching Pembrolizumab Dosage From 200 mg Every 3 Weeks to 400 mg Every 6 Weeks in Patients With Advanced NSCLC.
J Thorac Oncol. 2024;19:e33-e34.
PubMed

HAN Z, Liu L, Jiang Y
Suggestions for the predictive factors related to irAES and research methods during dose switching of pembrolizumab treatment in patients with advanced NSCLC.
J Thorac Oncol. 2024;19:e31-e32.
PubMed

ANDERSEN H, Aro M, Kaarteenaho R, Koivunen J, et al
Lung Cancer in Finland.
J Thorac Oncol. 2024;19:1265-1271.
PubMed

YANG CY, Lee MR, Yang PC
Beyond Low-Dose Computed Tomography: Emerging Diagnostic Tools for Early Lung Cancer Detection.
J Thorac Oncol. 2024;19:1261-1264.
PubMed

ROSSI S, Costa R, di Federico A, Lo Bianco F, et al
Histopathological Evidence for a Non-Inflammatory Mechanism in Osimertinib-Induced Myopathy: A Case Report.
J Thorac Oncol. 2024;19:1352-1355.
PubMed Abstract available

LEVY A, Adebahr S, Hurkmans C, Ahmed M, et al
Stereotactic Body Radiotherapy for Centrally Located Inoperable Early-Stage NSCLC: EORTC 22113-08113 LungTech Phase II Trial Results.
J Thorac Oncol. 2024;19:1297-1309.
PubMed Abstract available

ROMA L, Ercan C, Conticelli F, Akyurek N, et al
Tracing Tumor Heterogeneity of Pleomorphic Carcinoma of the Lung.
J Thorac Oncol. 2024;19:1284-1296.
PubMed Abstract available

GILL RR, Nowak AK, Giroux DJ, Eisele M, et al
The International Association for the Study of Lung Cancer Mesothelioma Staging Project: Proposals for Revisions of the "T" Descriptors in the Forthcoming Ninth Edition of the TNM Classification for Pleural Mesothelioma.
J Thorac Oncol. 2024;19:1310-1325.
PubMed Abstract available

August 2024

ZHOU Q, Meng X, Sun L, Huang D, et al
Efficacy and safety of KRAS G12C inhibitor IBI351 monotherapy in patients with advanced non-small cell lung cancer: results from a phase 2 pivotal study.
J Thorac Oncol. 2024 Aug 8:S1556-0864(24)00762.
PubMed Abstract available

HUBER RM, Cavic M, Balata H, Kitts AB, et al
From the IASLC Early Detection and Screening Committee Terminology Issues in Screening and Early Detection of Lung Cancer - IASLC Early Detection and Screening Committee Expert Group Recommendations.
J Thorac Oncol. 2024 Aug 2:S1556-0864(24)00747.
PubMed Abstract available

ERNST SM, von der Thusen JH, Dubbink HJ, Dingemans AC, et al
Letter Regarding "Clinical Utility of Circulating Tumor DNA in Patients With Advanced KRASG12C-Mutated NSCLC Treated With Sotorasib".
J Thorac Oncol. 2024;19:e29-e30.
PubMed

KOSAKA N, Kataoka Y
Letter Regarding "Clinical Utility of Circulating Tumor DNA in Patients With Advanced KRASG12C-Mutated NSCLC Treated With Sotorasib".
J Thorac Oncol. 2024;19:e28.
PubMed

CAMERON RB, Hines JB, Torri V, Garassino MC, et al
A Response Letter by Cameron et al.
J Thorac Oncol. 2024;19:e26-e28.
PubMed

HUANG J, Osarogiagbon RU
Author's Reply.
J Thorac Oncol. 2024;19:e24.
PubMed

PONVILAWAN B, Subramanian J, Bansal D
The Number of Chemoimmunotherapy Cycles and Clinical Outcomes in Resectable NSCLC.
J Thorac Oncol. 2024;19:e24-e26.
PubMed

TRISOLINI R
The Devil Is in the Details: A Hidden Obstacle to Implementing the Proposed Revision of the N Descriptors in the Ninth Edition of the TNM Classification for Lung Cancer.
J Thorac Oncol. 2024;19:e23.
PubMed

KUBO N
Response to Letter to the Editor.
J Thorac Oncol. 2024;19:e22.
PubMed

SHI L, Bao Z
Accurate Prognostic Factor for Carbon-Ion Radiotherapy in Operable Stage I NSCLC.
J Thorac Oncol. 2024;19:e21-e22.
PubMed

SILVESTRI GA, Young RP, Tanner NT, Mazzone P, et al
Screening Low-Risk Individuals for Lung Cancer: The Need May Be Present, but the Evidence of Benefit Is Not.
J Thorac Oncol. 2024;19:1155-1163.
PubMed Abstract available

MAKAREM M, Janne PA
"Tumor-Free Survival" Outweighs the Side Effects of Combined Anti-EGF Therapy and Chemotherapy in Patients With NSCLC.
J Thorac Oncol. 2024;19:1151-1154.
PubMed

ZHENG MM, Wu YL
"Tumor-free survival" Does Not Outweigh the Adverse Effects of Anti-EGFR Therapy and Chemotherapy in Patients With NSCLC.
J Thorac Oncol. 2024;19:1146-1150.
PubMed

LAISAAR T, Innos K, Jaal J, Oselin K, et al
Lung Cancer in Estonia.
J Thorac Oncol. 2024;19:1138-1145.
PubMed

WOODARD GA, Jablons DM
Shades of Gray: Do Never Smokers Benefit From Lung Cancer Screening Programs?
J Thorac Oncol. 2024;19:1135-1137.
PubMed

TURK MA
Editorial Comment: Validation Study for the N Descriptor of the Newly Proposed 9th Edition of the TNM Staging System Proposed by the International Association for the Study of Lung Cancer.
J Thorac Oncol. 2024;19:1133-1134.
PubMed

PERRONE F, Leonetti A, Tiseo M, Facchinetti F, et al
Benefit With No Target: Long-Term Outcomes of Chemoimmunotherapy in "PD-L1 Negative" NSCLC.
J Thorac Oncol. 2024;19:1128-1132.
PubMed

GRAY SG, Mutti L, Meirson T
Encouraging Fussy Eaters in EGFR-Mutated Lung Cancer.
J Thorac Oncol. 2024;19:1125-1127.
PubMed

HU LY, Zhuang WT, Chen MJ, Liao J, et al
EGFR Oncogenic Mutations in NSCLC Impair Macrophage Phagocytosis and Mediate Innate Immune Evasion Through Up-Regulation of CD47.
J Thorac Oncol. 2024;19:1186-1200.
PubMed Abstract available

WOLF AS, Eisele M, Giroux DJ, Gill R, et al
The International Association for the Study of Lung Cancer Pleural Mesothelioma Staging Project: Expanded Database to Inform Revisions in the Ninth Edition of the TNM Classification of Pleural Mesothelioma.
J Thorac Oncol. 2024;19:1242-1252.
PubMed Abstract available

July 2024

VAN ROSSUM PSN, Wolfhagen N, van Bockel LW, Coremans IEM, et al
Real-world acute toxicity and 90-day mortality in patients with stage I non-small cell lung cancer treated with stereotactic body radiotherapy.
J Thorac Oncol. 2024 Jul 25:S1556-0864(24)00684.
PubMed Abstract available

JENSEN SO, Moore DA, Surani AA, Crosbie PA, et al
Second Primary Lung Cancer - an emerging issue in lung cancer survivors.
J Thorac Oncol. 2024 Jul 24:S1556-0864(24)00683.
PubMed Abstract available

GRAY JE, Markovets A, Reungwetwattana T, Majem M, et al
Longitudinal Analyses of Circulating-Tumor DNA for Detection of EGFR Mutation-Positive Advanced Non-Small Cell Lung Cancer Progression During Treatment: Data From FLAURA and AURA3.
J Thorac Oncol. 2024 Jul 17:S1556-0864(24)00676.
PubMed Abstract available

JUN S, Shukla NA, Durm G, Hui AB, et al
Analysis of Circulating Tumor DNA Predicts Outcomes of Short Course Consolidation Immunotherapy in Unresectable Stage III Non-Small Cell Lung Cancer.
J Thorac Oncol. 2024 Jul 4:S1556-0864(24)00664.
PubMed Abstract available

LIN YL, Wang GS, Wei JC
Rheumatoid Arthritis and Risk of Lung Cancer.
J Thorac Oncol. 2024;19:e15-e16.
PubMed

YANG JJ, Wen W, Zheng W, Shu XO, et al
"Some Thoughts on Lung Cancer Risk Prediction Models for Long-Term Smokers in Asia".
J Thorac Oncol. 2024;19:e14-e15.
PubMed

SHEN LT, Chen HL
Some Thoughts on Lung Cancer Risk Prediction Models for Long-Term Smokers in Asia.
J Thorac Oncol. 2024;19:e13-e14.
PubMed

AFRIYIE-MENSAH JS, Dadzie MA, Vanderpuye VDNK, Calys-Tagoe B, et al
Lung Cancer in Ghana.
J Thorac Oncol. 2024;19:966-972.
PubMed

MOCHIZUKI A, Shiraishi K, Honda T, Higashiyama RI, et al
Passive Smoking-Induced Mutagenesis as a Promoter of Lung Carcinogenesis.
J Thorac Oncol. 2024;19:984-994.
PubMed Abstract available

June 2024

SPICER JD, Cascone T, Wynes MW, Ahn MJ, et al
Neoadjuvant and Adjuvant Treatment for Early-Stage Resectable Non-small Cell Lung Cancer (NSCLC): Consensus Recommendations from the International Association for the Study of Lung Cancer (IASLC).
J Thorac Oncol. 2024 Jun 18:S1556-0864(24)00627.
PubMed Abstract available

HSU CK, Lai CC
Association Between Rheumatoid Arthritis and the Risk of Lung Cancer.
J Thorac Oncol. 2024;19:e9.
PubMed

URBANSKA EM, Sorensen JB, Santoni-Rugiu E
Finding One Treatment for All Advanced EGFR-positive NSCLC-An Infinite Task.
J Thorac Oncol. 2024;19:e11-e12.
PubMed

CHO MH, Cho JH, Shin DW
In Response.
J Thorac Oncol. 2024;19:e10.
PubMed

RICCIUTI B, Garassino MC
Precision Immunotherapy for STK11/KEAP1-Mutant NSCLC.
J Thorac Oncol. 2024;19:877-882.
PubMed

DICKHOFF C, Heineman DJ, van Dorp M, Senan S, et al
The Surgical Resection Difficulty From Neoadjuvant Chemoimmunotherapy Is Minimal and Neoadjuvant Therapy Should Be the Standard.
J Thorac Oncol. 2024;19:862-865.
PubMed

UGALDE FIGUEROA P, Lacroix V, Van Schil PE
Neoadjuvant Chemoimmunotherapy Complicates Subsequent Surgical Resection and Adjuvant Immunotherapy Is Preferable From the Surgical Standpoint.
J Thorac Oncol. 2024;19:858-861.
PubMed

LI MS, Ou SI
Iruplinalkib (WX-0593), the Seventh ALK Tyrosine Kinase Inhibitor Approved in People's Republic of China With More to Come.
J Thorac Oncol. 2024;19:855-857.
PubMed

PECCATORI FA, Florez N, Imbimbo M
From Approximation to Precision: Fertility and Pregnancy Questions in Young Patients With Lung Cancer.
J Thorac Oncol. 2024;19:852-854.
PubMed

May 2024

ROCCO G, Pennazza G, Tan KS, Vanstraelen S, et al
A real-world assessment of stage I lung cancer through electronic nose technology.
J Thorac Oncol. 2024 May 16:S1556-0864(24)00211.
PubMed Abstract available

BILLE A, Ripley RT, Giroux DJ, Gill RR, et al
The International Association for the Study of Lung Cancer Mesothelioma Staging Project: Proposals for the "N" Descriptors in the Forthcoming Ninth Edition of the TNM Classification for Pleural Mesothelioma.
J Thorac Oncol. 2024 May 9:S1556-0864(24)00208.
PubMed Abstract available

NOWAK AK, Giroux DJ, Eisele M, Rosenthal A, et al
The International Association for the Study of Lung Cancer Pleural Mesothelioma Staging Project: Proposal for Revision of the TNM Stage Groupings in the Forthcoming (Ninth) Edition of the TNM Classification for Pleural Mesothelioma.
J Thorac Oncol. 2024 May 9:S1556-0864(24)00207.
PubMed Abstract available

NASSAR AH, Kim SY, Adib E, Naqash AR, et al
Response letter by Nassar et al.
J Thorac Oncol. 2024;19:e7-e8.
PubMed

CHEN CY, Wang GS, Wei JC
Comment on "Consolidation Osimertinib Versus Durvalumab following Concurrent Chemoradiation in Unresectable EGFR-Mutant NSCLC".
J Thorac Oncol. 2024;19:e6-e7.
PubMed

ZHAO B, Yao L, Ma W
Osimertinib Versus Durvalumab Versus Observation After Chemoradiation in Unresectable EGFR-Mutant NSCLC.
J Thorac Oncol. 2024;19:e5-e6.
PubMed

SRINIVASALU VK, Patnaik RS, Kiong LS, Justin JS, et al
Lung Cancer in Brunei Darussalam.
J Thorac Oncol. 2024;19:698-705.
PubMed

LI Y, Adusumilli PS, Chou TY, Kadota K, et al
Pro: "Is Spread Through Air Spaces an In Vivo Phenomenon or an Inducible Artifact?".
J Thorac Oncol. 2024;19:677-697.
PubMed Abstract available

BLAAUWGEERS H, Dickhoff C, Pelosi G, Timens W, et al
Con: "Is Spread Through Air Spaces an In Vivo Phenomenon or an Inducible Artifact?".
J Thorac Oncol. 2024;19:671-676.
PubMed

SHIH JY
ERBB2 Amplification in NSCLC: How Many Faces?
J Thorac Oncol. 2024;19:668-670.
PubMed

ISHIKAWA S
Artificial Intelligence Enhances NSCLC Care by Predicting Treatment Outcomes, Validating Neoadjuvant Therapies, and Improving Precision.
J Thorac Oncol. 2024;19:666-667.
PubMed

WOODARD GA, Dacic S
Should the TNM Staging of NSCLC Evolve Beyond Anatomical Descriptors?
J Thorac Oncol. 2024;19:663-665.
PubMed

LUO J, Sanchez M, Lee E, Hertzler H, et al
Initial Chemotherapy for Locally Advanced and Metastatic NUT Carcinoma.
J Thorac Oncol. 2024;19:829-838.
PubMed Abstract available

OU SI, Hagopian GG, Zhang SS, Nagasaka M, et al
Comprehensive Review of ROS1 Tyrosine Kinase Inhibitors-Classified by Structural Designs and Mutation Spectrum (Solvent Front Mutation [G2032R] and Central beta-Sheet 6 [Cbeta6] Mutation [L2086F]).
J Thorac Oncol. 2024;19:706-718.
PubMed Abstract available

April 2024

GADGEEL SM, Rodriguez-Abreu D, Halmos B, Garassino MC, et al
Pembrolizumab Plus Chemotherapy for Metastatic Non-Small-Cell Lung Cancer With Programmed Cell Death Ligand 1 Tumor Proportion Score Less Than 1%: Pooled Analysis of Outcomes After 5 Years of Follow-Up.
J Thorac Oncol. 2024 Apr 18:S1556-0864(24)00169.
PubMed Abstract available

ERNST SM, van Marion R, Atmodimedjo PN, de Jonge E, et al
Clinical utility of circulating tumor DNA in patients with advanced KRAS(G12C)-mutated non-small cell lung cancer treated with sotorasib.
J Thorac Oncol. 2024 Apr 12:S1556-0864(24)00165.
PubMed Abstract available

HORNE A, Harada K, Brown KD, Chua KLM, et al
Treatment response biomarkers: working towards personalised radiotherapy for lung cancer.
J Thorac Oncol. 2024 Apr 12:S1556-0864(24)00164.
PubMed Abstract available

KIM IH, Lee GD, Choi S, Kim HR, et al
Validation Study for the N Descriptor of the Newly Proposed 9th Edition of the TNM Staging System Proposed by the International Association for the Study of Lung Cancer.
J Thorac Oncol. 2024 Apr 11:S1556-0864(24)00160.
PubMed Abstract available

SHUKLA V, Wang H, Varticovski L, Baek S, et al
Genome-wide Analysis Identifies Nuclear Factor 1C as a Novel Transcription Factor and Potential Therapeutic Target in Small Cell Lung Cancer.
J Thorac Oncol. 2024 Apr 5:S1556-0864(24)00131.
PubMed Abstract available

DETTERBECK FC, Ostrowski M, Hoffmann H, Rami-Porta R, et al
The IASLC Lung Cancer Staging Project: Proposals for Revision of the Classification of Residual Tumor after Resection for the Forthcoming (9(th)) Edition of the TNM Classification of Lung Cancer.
J Thorac Oncol. 2024 Apr 1:S1556-0864(24)00129.
PubMed Abstract available

CHANG CL, Lin KC, Chen WM, Shia BC, et al
Correspondence: Intensity-Modulated Proton Therapy Versus Intensity-Modulated Radiotherapy for Inoperable Esophageal Squamous Cell Carcinoma: Methodologic Issues.
J Thorac Oncol. 2024;19:e2-e4.
PubMed

CHIOU CC, Lai TY
Intensity-Modulated Proton Therapy Versus Intensity-Modulated Radiotherapy for Inoperable Esophageal Squamous Cell Carcinoma: Methodologic Issues.
J Thorac Oncol. 2024;19:e1-e2.
PubMed

SMESSEIM I, Baas P
Immunotherapy Is a Good Standard Option for Patients With Malignant Pleural Mesothelioma, Despite the Real-World Results From Australia.
J Thorac Oncol. 2024;19:547-550.
PubMed

GRAY SG, Meirson T, Mutti L
Based on the Real-World Results From Australia, Immunotherapy Is Not a Good Option for Patients With Mesothelioma.
J Thorac Oncol. 2024;19:541-546.
PubMed

SAIFO M, Alali M, Alhabeb H, Awak M, et al
Lung Cancer in Syria.
J Thorac Oncol. 2024;19:534-540.
PubMed

SHOENBILL KA, Goldstein AO
Better Together: Advancing Tobacco Use Treatment and Lung Cancer Screening.
J Thorac Oncol. 2024;19:531-533.
PubMed

ZHU Z, Chen H
Additional Evidence for Postoperative Radiation Therapy on Thymic Carcinoma.
J Thorac Oncol. 2024;19:528-530.
PubMed

LEE JB, Nagasaka M
Translational Research in ROS1-Positive NSCLC: Are We Moving Out of the Six Blind Men and the Elephant Stage?
J Thorac Oncol. 2024;19:525-527.
PubMed

LEONG TL, McWilliams A, Wright GM
Incidental Pulmonary Nodules: An Opportunity to Complement Lung Cancer Screening.
J Thorac Oncol. 2024;19:522-524.
PubMed

DWYER LJ, Singhal N, Yu B, Kao S, et al
Successful Osimertinib Rechallenge After Relapse Following Adjuvant Osimertinib: A Case Report.
J Thorac Oncol. 2024;19:650-652.
PubMed Abstract available

RIMNER A, Ahmad U, Lobaugh SM, Zhang Z, et al
Postoperative Radiation Therapy for Thymic Carcinoma: An Analysis of the International Thymic Malignancy Interest Group/European Society of Thoracic Surgeons Database.
J Thorac Oncol. 2024;19:626-635.
PubMed Abstract available

MCNAMEE N, Harvey C, Gray L, Khoo T, et al
Brief Report: Real-World Toxicity and Survival of Combination Immunotherapy in Pleural Mesothelioma-RIOMeso.
J Thorac Oncol. 2024;19:636-642.
PubMed Abstract available

NEL AE, Pavlisko EN, Roggli VL
The Interplay Between the Immune System, Tumor Suppressor Genes, and Immune Senescence in Mesothelioma Development and Response to Immunotherapy.
J Thorac Oncol. 2024;19:551-564.
PubMed Abstract available

March 2024

TRAVIS WD, Eisele M, Nishimura KK, Aly R, et al
The IASLC Lung Cancer Staging Project: Recommendation to Introduce Spread Through Air Spaces (STAS) as a Histologic Descriptor in the 9(th) Edition of the TNM Classification of Lung Cancer.Analysis of 4,061 Pathologic Stage I Non-Small cell Lung Carci
J Thorac Oncol. 2024 Mar 18:S1556-0864(24)00122.
PubMed Abstract available

BORGEAUD M, Parikh K, Banna GL, Kim F, et al
Unveiling the Landscape of uncommon EGFR Mutations in Non-Small Cell Lung Cancer - A Systematic Review.
J Thorac Oncol. 2024 Mar 16:S1556-0864(24)00123.
PubMed Abstract available

HINES JB, Cameron RB, Esposito A, Kim L, et al
Evaluation of MPR and pCR as surrogate endpoints for survival in randomized controlled trials of neoadjuvant immune checkpoint blockade in resectable in non-small cell lung cancer.
J Thorac Oncol. 2024 Mar 8:S1556-0864(24)00117.
PubMed Abstract available

CHENG Y, Fan Y, Zhao Y, Huang D, et al
Tislelizumab Plus Platinum and Etoposide Versus Placebo Plus Platinum and Etoposide as First-Line Treatment for Extensive-Stage Small Cell Lung Cancer (RATIONALE-312): a Multicenter, Double-Blind, Placebo-Controlled, Randomized, Phase 3 Clinical Trial
J Thorac Oncol. 2024 Mar 7:S1556-0864(24)00115.
PubMed Abstract available

RAMI-PORTA R, Nishimura KK, Giroux DJ, Detterbeck F, et al
The IASLC Lung Cancer Staging Project: Proposals for Revision of the TNM Stage Groups in the Forthcoming (Ninth) Edition of the TNM Classification for Lung Cancer.
J Thorac Oncol. 2024 Mar 4:S1556-0864(24)00079.
PubMed Abstract available

KIM BG, Yoon S, Lee SY, Sohn JW, et al
How Does Rheumatoid Arthritis Increase the Risk of Lung Cancer?
J Thorac Oncol. 2024;19:509-510.
PubMed

WERNER RS, Curioni-Fontecedro A, Mauti LA, Addeo A, et al
Lung Cancer in Switzerland.
J Thorac Oncol. 2024;19:385-394.
PubMed

TEN HAAF K
Considerations for Enhancing Lung Cancer Risk Prediction and Screening in Asian Populations.
J Thorac Oncol. 2024;19:373-375.
PubMed

LI CP, Tsai RY, Chang HC, Gau SY, et al
Survival and Prognosis After Carbon-Ion Radiotherapy in Patients With NSCLC.
J Thorac Oncol. 2024;19:507-508.
PubMed

CHEN LN, Lee ATM, Nagasaka M, Ou SI, et al
Chemotherapy and Osimertinib Combination Should Be the First-Line Treatment for All Advanced EGFR+ NSCLC.
J Thorac Oncol. 2024;19:380-384.
PubMed

LIM SM, Lee JB, Cho BC
Chemotherapy and Osimertinib Combination Should Not Be the First-Line Treatment for All Advanced EGFR+ NSCLC.
J Thorac Oncol. 2024;19:376-379.
PubMed

YALAMANCHALI A, Hassan KA
MUC1-C: The Occam Razor of Osimertinib Resistance?
J Thorac Oncol. 2024;19:370-372.
PubMed

DAMMEIJER F, Dumoulin DW, Aerts JGJV
Anti-Vascular Endothelial Growth Factor/Programmed Cell Death Protein 1 Bispecific Antibodies: Using Nunchucks to Fight an Old Adversary.
J Thorac Oncol. 2024;19:366-369.
PubMed

CANI M, Novello S, Bironzo P
Mismatch Repair Deficiency in Lung Tumors: Adding a New Layer of Complexity on Pie Slices.
J Thorac Oncol. 2024;19:363-365.
PubMed

BORCZUK AC
Invasive Size in Lung Adenocarcinoma-Reproducible Criteria, More Accurate Staging.
J Thorac Oncol. 2024;19:360-362.
PubMed

YANG SR, Gedvilaite E, Ptashkin R, Chang J, et al
Microsatellite Instability and Mismatch Repair Deficiency Define a Distinct Subset of Lung Cancers Characterized by Smoking Exposure, High Tumor Mutational Burden, and Recurrent Somatic MLH1 Inactivation.
J Thorac Oncol. 2024;19:409-424.
PubMed Abstract available

February 2024

FONG KM, Rosenthal A, Giroux DJ, Nishimura KK, et al
The IASLC Lung Cancer Staging Project: Proposals for the Revision of the M Descriptors in the Forthcoming 9th edition of the TNM Classification of Lung Cancer.
J Thorac Oncol. 2024 Feb 4:S1556-0864(24)00060.
PubMed Abstract available

ZHOU RX, Liao HJ, Hu JJ, Xiong H, et al
Global burden of lung cancer attributable to household fine particulate matter pollution in 204 countries and territories, 1990-2019.
J Thorac Oncol. 2024 Feb 2:S1556-0864(24)00034.
PubMed Abstract available

TORASAWA M, Horinouchi H
A Response to the Letter to the Editor: "A Paradigm Shift in First-Line Treatment Can Have Many Implications for Second-Line Treatment".
J Thorac Oncol. 2024;19:351-352.
PubMed

NISHIMURA T
A Paradigm Shift in First-Line Treatment Can Have Many Implications For Second-Line Treatment.
J Thorac Oncol. 2024;19:350.
PubMed

HORITA N, Takase-Minegishi K
Information Bias Might Exaggerate Lung Cancer Risk of Patients With Rheumatoid Arthritis.
J Thorac Oncol. 2024;19:348.
PubMed

CHANG HC, Gau SY
Real-World Evidence of the Association Between Rheumatoid Arthritis and Lung Cancer.
J Thorac Oncol. 2024;19:346.
PubMed

YUAN C, Huang R, Wang Y
An Error in Modeling and the Selection of Independent Radiomics Variables Need Caution.
J Thorac Oncol. 2024;19:344-345.
PubMed

BERMAS BL, Gerber DE
The Joint Problem of Rheumatoid Arthritis and Lung Cancer.
J Thorac Oncol. 2024;19:196-198.
PubMed

VOKES EE, Mornex F, Sezer A, Cheng Y, et al
Bintrafusp Alfa With CCRT Followed by Bintrafusp Alfa Versus Placebo With CCRT Followed by Durvalumab in Patients With Unresectable Stage III NSCLC: A Phase 2 Randomized Study.
J Thorac Oncol. 2024;19:285-296.
PubMed Abstract available

REMON J, Saw SPL, Cortiula F, Singh PK, et al
Perioperative Treatment Strategies in EGFR-Mutant Early-Stage NSCLC: Current Evidence and Future Challenges.
J Thorac Oncol. 2024;19:199-215.
PubMed Abstract available

DACIC S, Cao X, Bota-Rabassedas N, Sanchez-Espiridion B, et al
Genomic Staging of Multifocal Lung Squamous Cell Carcinomas Is Independent of the Comprehensive Morphologic Assessment.
J Thorac Oncol. 2024;19:273-284.
PubMed Abstract available

OWONIKOKO TK
SCLC Classification by Platinum Sensitivity in the Era of Immunotherapy: Mere Relic or a Valuable Treasure to Keep?
J Thorac Oncol. 2024;19:193-195.
PubMed

LE X
Partners in Crime: Co-Occurring Genetic Alterations in EGFR-Mutant NSCLC.
J Thorac Oncol. 2024;19:190-192.
PubMed

LEE JH
Is Real-World Evidence on Acquired Resistance to Osimertinib Relevant Clinically?
J Thorac Oncol. 2024;19:187-189.
PubMed

SHIRAISHI Y, Tokito T, Toyozawa R, Inagaki C, et al
Five Cases of Cytokine Release Syndrome in Patients Receiving Cytotoxic Chemotherapy Together With Nivolumab Plus Ipilimumab: A Case Report.
J Thorac Oncol. 2024;19:337-343.
PubMed Abstract available

January 2024

SHI Y, Hu X, Li X, Gong C, et al
Ficonalkib (SY-3505) in Advanced ALK-Positive Non-Small-Cell Lung Cancer: A Multicenter, Open-Label, Single-Arm, Phase I/? Study.
J Thorac Oncol. 2024 Jan 29:S1556-0864(24)00035.
PubMed Abstract available

SHI Y, Chen J, Yang R, Wu H, et al
Iruplinalkib (WX-0593) versus crizotinib in ALK TKI-naive locally advanced or metastatic ALK-positive non-small cell lung cancer: interim analysis of a randomized, open-label, phase III study (INSPIRE).
J Thorac Oncol. 2024 Jan 25:S1556-0864(24)00033.
PubMed Abstract available

NASSAR AH, Kim SY, Aredo JV, Feng J, et al
Consolidation Osimertinib versus Durvalumab versus Observation following Concurrent Chemoradiation in Unresectable EGFR-Mutant Non-Small-Cell Lung Cancer: A Multicenter Retrospective Cohort Study.
J Thorac Oncol. 2024 Jan 24:S1556-0864(24)00032.
PubMed Abstract available

SIMONS E, Camidge DR
Lung cancer oncogene-directed therapy, fertility and pregnancy.
J Thorac Oncol. 2024 Jan 5:S1556-0864(24)00023.
PubMed Abstract available

YU S, Feng J
Comment on "Durvalumab After Sequential Chemoradiotherapy in Stage III, Unresectable NSCLC: The Phase 2 PACIFIC-6 Trial".
J Thorac Oncol. 2024;19:173-174.
PubMed

TANIZAKI J, Hayashi H
Unraveling Pseudo Kidney Injury: The Significance of Understanding Our "MATE" in Molecular-Targeted Therapies.
J Thorac Oncol. 2024;19:15-17.
PubMed

BATAH H, Majeed Z, Moudgil R
Tale of Two Cs: Inter-Relationship Between Cardiovascular and Lung Cancer.
J Thorac Oncol. 2024;19:13-14.
PubMed

SINGHAL S, Gandara D, Riess JW
Mapping EGFR Exon 20 Resistance Mutations: An Intricate Landscape.
J Thorac Oncol. 2024;19:10-12.
PubMed

FANG W, Girard N, Cilento V, Goren E, et al
The International Association for the Study of Lung Cancer Thymic Epithelial Tumors Staging Project: Proposals for the N and the M Components for the Forthcoming (Ninth) Edition of the TNM Classification of Malignant Tumors.
J Thorac Oncol. 2024;19:52-70.
PubMed Abstract available

CHEN MF, Harada G, Liu D, DeMatteo R, et al
Brief Report: Tyrosine Kinase Inhibitors for Lung Cancers That Inhibit MATE-1 Can Lead to "False" Decreases in Renal Function.
J Thorac Oncol. 2024;19:153-159.
PubMed Abstract available

UDAGAWA H, Nilsson MB, Robichaux JP, He J, et al
HER4 and EGFR Activate Cell Signaling in NRG1 Fusion-Driven Cancers: Implications for HER2-HER3-specific Versus Pan-HER Targeting Strategies.
J Thorac Oncol. 2024;19:106-118.
PubMed Abstract available

HAMADA A, Suda K, Nishino M, Obata K, et al
Secondary Mutations of the EGFR Gene That Confer Resistance to Mobocertinib in EGFR Exon 20 Insertion.
J Thorac Oncol. 2024;19:71-79.
PubMed Abstract available

LAM S, Wynes MW, Connolly C, Ashizawa K, et al
The International Association for the Study of Lung Cancer Early Lung Imaging Confederation Open-Source Deep Learning and Quantitative Measurement Initiative.
J Thorac Oncol. 2024;19:94-105.
PubMed Abstract available

TAGLIAMENTO M, Di Maio M, Remon J, Bironzo P, et al
Meta-Analysis on the Combination of Chemotherapy With Programmed Death-Ligand 1 and Programmed Cell Death Protein 1 Blockade as First-Line Treatment for Unresectable Pleural Mesothelioma.
J Thorac Oncol. 2024;19:166-172.
PubMed Abstract available

December 2023

YANG JC, Han B, De La Mora Jimenez E, Lee JS, et al
Pembrolizumab With or Without Lenvatinib for First-Line Metastatic Non?Small-Cell Lung Cancer With PD-L1 Tumor Proportion Score >/=1% (LEAP-007): A Randomized, Double-Blind, Phase 3 Trial.
J Thorac Oncol. 2023 Dec 28:S1556-0864(23)02432.
PubMed Abstract available

ODINTSOV I, Makarem M, Nishino M, Bachert SE, et al
Prevalence and Therapeutic Targeting of High Level ERBB2 Amplification in Non-Small Cell Lung Cancer.
J Thorac Oncol. 2023 Dec 26:S1556-0864(23)02428.
PubMed Abstract available

BISCHOFF P, Reck M, Overbeck T, Christopoulos P, et al
Outcome of first-line treatment with pembrolizumab according to KRAS/TP53 mutational status for non-squamous PD-L1 high (>/=50%) NSCLC in the German National Network Genomic Medicine Lung Cancer (nNGM).
J Thorac Oncol. 2023 Dec 12:S1556-0864(23)02423.
PubMed Abstract available

VAN SCHIL PE, Asamura H, Nishimura KK, Rami-Porta R, et al
The IASLC Lung Cancer Staging Project: Proposals for the Revisions of the T Descriptors in the Forthcoming Ninth Edition of the TNM Classification for Lung Cancer.
J Thorac Oncol. 2023 Dec 7:S1556-0864(23)02411.
PubMed Abstract available

LI W, Fei K, Guo L, Wang Y, et al
CD74/SLC34A2-ROS1 fusion variants involving the transmembrane region predict poor response to crizotinib in non-small cell lung cancer independent of TP53 mutations.
J Thorac Oncol. 2023 Dec 7:S1556-0864(23)02414.
PubMed Abstract available

DACIC S, Travis WD, Giltnane JM, Kos F, et al
Artificial intelligence-powered assessment of pathologic response to neoadjuvant atezolizumab in patients with non-small cell lung cancer: results from the LCMC3 study.
J Thorac Oncol. 2023 Dec 7:S1556-0864(23)02415.
PubMed Abstract available

XHEMALAJ D, Gradica F, Skenduli I, Tula J, et al
Lung Cancer in Albania.
J Thorac Oncol. 2023;18:1632-1637.
PubMed

FERREIRA M, Redman MW, Reckamp KL
Moving Toward Rationale Phase 3 Designs for Advanced NSCLC.
J Thorac Oncol. 2023;18:1629-1631.
PubMed

LI Z, Lu S
Third-Generation EGFR Tyrosine Kinase Inhibitor for Central Nervous System Metastases EGFR-Mutant NSCLC: Current Evidence and Future Perspectives.
J Thorac Oncol. 2023;18:1625-1628.
PubMed

MAKAREM M, Rotow JK
Genotype Versus Phenotype: Defining Predictive Biomarkers of Immunotherapy Response.
J Thorac Oncol. 2023;18:1615-1617.
PubMed

RUFFINI E, Huang J, Cilento V, Goren E, et al
The International Association for the Study of Lung Cancer Thymic Epithelial Tumors Staging Project: Proposal for a Stage Classification for the Forthcoming (Ninth) Edition of the TNM Classification of Malignant Tumors.
J Thorac Oncol. 2023;18:1655-1671.
PubMed Abstract available

MAROM EM, Fang W, Ruffini E, Detterbeck F, et al
The International Association for the Study of Lung Cancer Thymic Epithelial Tumor Staging Project: A Re-Assessment of the International Thymic Malignancy Interest Group/International Association for the Study of Lung Cancer Lymph Node Map for Thymic
J Thorac Oncol. 2023;18:1672-1688.
PubMed Abstract available

OKUMURA M, Marino M, Cilento V, Goren E, et al
The International Association for the Study of Lung Cancer Thymic Epithelial Tumor Staging Project: Proposal for the T Component for the Forthcoming (Ninth) Edition of the TNM Classification of Malignant Tumors.
J Thorac Oncol. 2023;18:1638-1654.
PubMed Abstract available

ANG YLE, Soo RA
Has the Ship Sailed on Second-Generation ALK Tyrosine Kinase Inhibitors in the Post-Crizotinib Setting?
J Thorac Oncol. 2023;18:1621-1624.
PubMed

MEDINA CG, Xu Y, Ripley RT
International Prognostic Modeling: A Platform for Collaborative Approach for Patients With Mesothelioma.
J Thorac Oncol. 2023;18:1618-1620.
PubMed

SOO RA, Cho BC, Kim JH, Ahn MJ, et al
Central Nervous System Outcomes of Lazertinib Versus Gefitinib in EGFR-Mutated Advanced NSCLC: A LASER301 Subset Analysis.
J Thorac Oncol. 2023;18:1756-1766.
PubMed Abstract available

WOLF AS, Rosenthal A, Giroux DJ, Nowak AK, et al
The International Association for the Study of Lung Cancer Pleural Mesothelioma Staging Project: Updated Modeling of Prognostic Factors in Pleural Mesothelioma.
J Thorac Oncol. 2023;18:1689-1702.
PubMed Abstract available

November 2023

WANG K, Du R, Myall NJ, Lewis WE, et al
BRIEF REPORT: Real-world efficacy and safety of amivantamab for EGFR-mutant non-small cell lung cancer (NSCLC).
J Thorac Oncol. 2023 Nov 25:S1556-0864(23)02376.
PubMed Abstract available

O'LEARY CL, Pierce N, Patel SP, Naidoo J, et al
Immune-Related Toxicity in Non-small cell Lung Cancer: Current State-of-The-Art and Emerging Clinical Challenges.
J Thorac Oncol. 2023 Nov 25:S1556-0864(23)02374.
PubMed Abstract available

LIAO W, Fehnel C, Goss J, Shepherd CJ, et al
Incidentally-Detected Lung Cancer in Persons Too Young or Too Old for Lung Cancer Screening in a Mississippi Delta Cohort.
J Thorac Oncol. 2023 Nov 18:S1556-0864(23)02371.
PubMed Abstract available

LU C, Wei XW, Wang Z, Zhou Z, et al
Allelic context of EGFR C797X mutant lung cancer defines four subtypes with heterogeneous genomic landscape and distinct clinical outcomes.
J Thorac Oncol. 2023 Nov 17:S1556-0864(23)02372.
PubMed Abstract available

HENSCHKE C, Huber R, Jiang L, Yang D, et al
Perspective on Management of LDCT Findings on Low-Dose Computed Tomography Examinations for Lung Cancer Screening From the IASLC Early Detection & Screening Committee.
J Thorac Oncol. 2023 Nov 16:S1556-0864(23)02369.
PubMed Abstract available

GULATI S, Ivic-Pavlicic T, Joasil J, Flores R, et al
Outcomes in Incidentally Versus Screening Detected Stage I Lung Cancer Surgery Patients.
J Thorac Oncol. 2023 Nov 15:S1556-0864(23)02364.
PubMed Abstract available

CARTMEL B, Fucito LM, Bold KW, Neveu S, et al
No Additional Effect of a Personalized Tobacco Treatment Intervention on Smoking Abstinence in Individuals Eligible for Lung Cancer Screening: Brief Report of a Randomized Trial.
J Thorac Oncol. 2023 Nov 15:S1556-0864(23)02368.
PubMed Abstract available

YANG JJ, Wen W, Zahed H, Zheng W, et al
Lung Cancer Risk Prediction Models for Asian Ever-Smokers.
J Thorac Oncol. 2023 Nov 7:S1556-0864(23)02352.
PubMed Abstract available

KUBO N, Suefuji H, Nakajima M, Tokumaru S, et al
Five-year survival outcomes after carbon-ion radiotherapy for operable stage I non-small cell lung cancer: a Japanese national registry study (J-CROS-LUNG).
J Thorac Oncol. 2023 Nov 2:S1556-0864(23)02346.
PubMed Abstract available

HARATAKE N, Ozawa H, Morimoto Y, Yamashita N, et al
MUC1-C IS A COMMON DRIVER OF ACQUIRED OSIMERTINIB RESISTANCE IN NON-SMALL CELL LUNG CANCER.
J Thorac Oncol. 2023 Nov 2:S1556-0864(23)02348.
PubMed Abstract available

HONG TH, Hwang S, Cho J, Choi YL, et al
Clinical Significance of the Proposed Pathologic Criteria for Invasion by the International Association for the Study of Lung Cancer in Resected Nonmucinous Lung Adenocarcinoma.
J Thorac Oncol. 2023 Nov 2:S1556-0864(23)02311.
PubMed Abstract available

QIU Z, Huang H, Zhang Y, Chen D, et al
Comment on "Plasma Progastrin-Releasing Peptide and Chromogranin A Assays for Diagnosing and Monitoring Lung Well-Differentiated Neuroendocrine Tumors: A Brief Report".
J Thorac Oncol. 2023;18:e138-e139.
PubMed

LI A, Yang Y, Zhang L, Hong S, et al
STK11/LKB1 and Immune Phenotypes Co-Determine Immunotherapy Outcomes.
J Thorac Oncol. 2023;18:e135-e138.
PubMed

AMORI G, Sugawara E, Inamura K
Leveraging Transcriptomics Data to Refine Immunotherapy Response Prediction in NSCLC: STK11 Deficiency and Beyond.
J Thorac Oncol. 2023;18:e134-e135.
PubMed

CHEN WM, Yu YH, Chen M, Shia BC, et al
Correspondence: The Causality Between Statin Use and Reduced Mortality of Esophageal Cancer Remains Unproven.
J Thorac Oncol. 2023;18:e132-e134.
PubMed

ZHANG Y, Dai K, He D, Chen Z, et al
The Causality Between Statin Use and Reduced Mortality of Esophageal Cancer Remains Unproven.
J Thorac Oncol. 2023;18:e130-e131.
PubMed

NIU Y, Yao F, Yang H
"Keaping" an Eye on the NRF2 Signature Score: Expanding Its Applicability in Lung Cancer.
J Thorac Oncol. 2023;18:e126-e128.
PubMed

MARTI JLG, Wells JZ, Wells A
Statins as a Secondary Preventive Agent for Metastatic Cancer.
J Thorac Oncol. 2023;18:e125-e126.
PubMed

OKONTA KE, Baiyewu LA, Jimoh MA
Lung Cancer in Nigeria.
J Thorac Oncol. 2023;18:1446-1457.
PubMed

DAGOGO-JACK I
We Don't Talk (Enough) About BRAF.
J Thorac Oncol. 2023;18:1443-1445.
PubMed

LEE JB, Ou SI
Plasma Genotyping From the CROWN, ALTA-1L, and ALEX Trials: Can We Speak With One Voice on What to Test, How to Test, When to Test, and for What Purpose?
J Thorac Oncol. 2023;18:1434-1442.
PubMed

HIJAZO-PECHERO S, Munoz-Pinedo C, Nadal E
A Transcriptomic Approach Outperforms Mutational Analysis to Identify KEAP1/NFE2L2 Pathway Activation in Patients With NSCLC.
J Thorac Oncol. 2023;18:1431-1433.
PubMed

SOZZI G, Pastorino U
Small RNAs Do It Better.
J Thorac Oncol. 2023;18:1428-1430.
PubMed

YANKELEVITZ DF, Yip R, Henschke CI
Considerations for Incorporating Family History Into Low-dose Computed Tomography Screening Recommendations.
J Thorac Oncol. 2023;18:1426-1427.
PubMed

SAKAI T, Matsumoto S, Ueda Y, Shibata Y, et al
Clinicogenomic Features and Targetable Mutations in NSCLCs Harboring BRAF Non-V600E Mutations: A Multi-Institutional Genomic Screening Study (LC-SCRUM-Asia).
J Thorac Oncol. 2023;18:1538-1549.
PubMed Abstract available

AHN MJ, Bondarenko I, Kalinka E, Cho BC, et al
Durvalumab in Combination With Olaparib Versus Durvalumab Alone as Maintenance Therapy in Metastatic NSCLC: The Phase 2 ORION Study.
J Thorac Oncol. 2023;18:1594-1606.
PubMed Abstract available

October 2023

WANG L, Luo Y, Ren S, Zhang Z, et al
A phase Ib study of ivonescimab, a PD-1/VEGF bispecific antibody, as first- or second-line therapy for advanced or metastatic immunotherapy naive non-small-cell lung cancer.
J Thorac Oncol. 2023 Oct 23:S1556-0864(23)02312.
PubMed Abstract available

HUANG J, Osarogiagbon RU, Giroux DJ, Nishimura KK, et al
The IASLC Lung Cancer Staging Project: Proposals for the Revision of the N Descriptors in the Forthcoming 9th Edition of the TNM Classification for Lung Cancer.
J Thorac Oncol. 2023 Oct 20:S1556-0864(23)02310.
PubMed Abstract available

CHO MH, Cho JH, Eun Y, Han K, et al
Rheumatoid arthritis and risk of lung cancer: a nationwide cohort study.
J Thorac Oncol. 2023 Oct 12:S1556-0864(23)02293.
PubMed Abstract available

STOCKHAMMER P, Grant M, Wurtz A, Foggetti G, et al
Co-occurring Alterations in Multiple Tumor Suppressor Genes are Associated with Worse Outcomes in Patients with EGFR-mutant Lung Cancer.
J Thorac Oncol. 2023 Oct 6:S1556-0864(23)02264.
PubMed Abstract available

HENSCHKE CI, Yip R, Sun Q, Li P, et al
Prospective Cohort Study to Compare Long-term Lung Cancer-Specific and All-Cause Survival of Clinical Early Stage (T1a-b;
J Thorac Oncol. 2023 Oct 6:S1556-0864(23)02265.
PubMed Abstract available

ROTOW JK, Lee JK, Madison RW, Oxnard GR, et al
Real-world genomic profile of EGFR second-site mutations and other osimertinib resistance mechanisms, and clinical landscape of non-small cell lung cancer (NSCLC) post-osimertinib.
J Thorac Oncol. 2023 Oct 6:S1556-0864(23)02263.
PubMed Abstract available

TRIPHURIDET N, Gao Y, Ou SI
Reply to Jayaraj et al. "Clinical Validity and Conceptual Interpretation of the Meta-Analysis on the Efficacy of LDCT Lung Cancer Screening in Never-Smokers".
J Thorac Oncol. 2023;18:e122-e123.
PubMed

JAYARAJ R, Shetty S, Ilankumaran S, Merchant Y, et al
Clinical Validity and Conceptual Interpretation of Low-Dose Computed Tomography Screening in Asian Female Never-Smokers Are as Efficacious in Detecting Lung Cancer as in Asian Male Ever-Smokers.
J Thorac Oncol. 2023;18:e118-e122.
PubMed

CHOUR A, Duruisseaux M
Response to Commentary on "Brief Report: Severe Sotorasib-Related Hepatotoxicity and Non-Liver Adverse Events Associated With Sequential Anti-PD(L)1 and Sotorasib Therapy in KRASG12C-Mutant Lung Cancer".
J Thorac Oncol. 2023;18:e114-e115.
PubMed

DETTERBECK FC, Asamura H, Rami-Porta R, Rusch VW, et al
The Only Constant Is Change: Introducing the International Association for the Study of Lung Cancer Proposals for the Ninth Edition of TNM Stage Classification of Thoracic Tumors.
J Thorac Oncol. 2023;18:1258-1260.
PubMed

INAMURA K
Exploiting Tumor Immune Microenvironment to Predict Response to Immunotherapy Plus Chemotherapy in NSCLC.
J Thorac Oncol. 2023;18:e109-e110.
PubMed

ADJEI AA
The Coming of a New Age: The Journal of Thoracic Oncology Goes Electronic in 2024.
J Thorac Oncol. 2023;18:1257.
PubMed

HOE HJ, Balasubramanian A, John T
LASERing FLAURAL Arrangements in Asian EGFR Subsets.
J Thorac Oncol. 2023;18:1261-1264.
PubMed

REUNGWETWATTANA T, Cho BC, Lee KH, Pang YK, et al
Lazertinib Versus Gefitinib Tyrosine Kinase Inhibitors in Treatment-Naive Patients With EGFR-Mutated Advanced NSCLC: Analysis of the Asian Subpopulation in LASER301.
J Thorac Oncol. 2023;18:1351-1361.
PubMed Abstract available

PEARSALL SM, Williamson SC, Humphrey S, Hughes E, et al
Lineage Plasticity in SCLC Generates Non-Neuroendocrine Cells Primed for Vasculogenic Mimicry.
J Thorac Oncol. 2023;18:1362-1385.
PubMed Abstract available

GELSOMINO F, Vitale G, Raschi E, Ardizzoni A, et al
Severe Liver Injury Triggered by Sequential Use of Immune Checkpoint Blockers and Tyrosine Kinase Inhibitors: An Emerging Clinical Issue.
J Thorac Oncol. 2023;18:e112-e113.
PubMed

CHEN WM, Yu YH, Chen M, Shia BC, et al
Correspondence: Statin Use During Concurrent Chemoradiotherapy With Improved Survival Outcomes in Esophageal Squamous Cell Carcinoma.
J Thorac Oncol. 2023;18:e107-e109.
PubMed

LIN TA, Chen SY, Chang R, Sun CK, et al
Correspondence: Statin Use During Concurrent Chemoradiotherapy With Improved Survival Outcomes in Esophageal Squamous Cell Carcinoma: A Propensity Score-Matched Nationwide Cohort Study.
J Thorac Oncol. 2023;18:e105-e106.
PubMed

WRIGHT K, Digby GC, Gyawali B, Jad R, et al
Malignant Superior Vena Cava Syndrome: A Scoping Review.
J Thorac Oncol. 2023;18:1268-1276.
PubMed Abstract available

EVANS WK, Tammemagi MC, Walker MJ, Cameron E, et al
Integrating Smoking Cessation Into Low-Dose Computed Tomography Lung Cancer Screening: Results of the Ontario, Canada Pilot.
J Thorac Oncol. 2023;18:1323-1333.
PubMed Abstract available

September 2023

DUAN J, Wu L, Yang K, Zhao J, et al
Safety, tolerability, pharmacokinetics, and preliminary efficacy of YK-029A in treatment-naive patients with advanced non-small cell lung cancer harboring EGFR exon 20 insertion mutations: A phase I trial.
J Thorac Oncol. 2023 Sep 28:S1556-0864(23)02259.
PubMed Abstract available

RECK M, Barlesi F, Chih-Hsin Yang J, Westeel V, et al
Avelumab vs platinum-based doublet chemotherapy as first-line treatment for patients with high-expression PD-L1+ metastatic non-small cell lung cancer: primary analysis from the phase 3 JAVELIN Lung 100 trial.
J Thorac Oncol. 2023 Sep 23:S1556-0864(23)02250.
PubMed Abstract available

JIANG C, Zhang Y, Fu F, Deng P, et al
A Shift in Paradigm: Selective Lymph Node Dissection for Minimizing Oversurgery in Early-Stage Lung Cancer.
J Thorac Oncol. 2023 Sep 23:S1556-0864(23)02245.
PubMed Abstract available

TORASAWA M, Horinouchi H, Nomura S, Igawa S, et al
Reconsidering the cutoff value for sensitive and refractory relapses in extensive-stage small cell lung cancer in the era of immunotherapy.
J Thorac Oncol. 2023 Sep 23:S1556-0864(23)02256.
PubMed Abstract available

WANG X, Bai H, Zhang J, Wang Z, et al
Genetic intra-tumour heterogeneity remodels the immune microenvironment and induces immune evasion in brain metastasis of lung cancer.
J Thorac Oncol. 2023 Sep 15:S1556-0864(23)01079.
PubMed Abstract available

FIGUEROA PU, Marques E, Cilento VJ, Giroux DJ, et al
Completeness of Resection and Long-term Survival of Patients Undergoing Resection for Pathological T3 Non-small-cell Lung Cancer: An International Association for the Study of Lung Cancer Analysis.
J Thorac Oncol. 2023 Sep 15:S1556-0864(23)01078.
PubMed Abstract available

ZHANG S, Liu L, Shi S, He H, et al
Bidirectional association between cardiovascular disease and lung cancer in a prospective cohort study.
J Thorac Oncol. 2023 Sep 11:S1556-0864(23)00806.
PubMed Abstract available

August 2023

DACIC S, Travis W, Redman M, Saqi A, et al
International Association for the Study of Lung Cancer Study of Reproducibility in Assessment of Pathologic Response in Resected Lung Cancers After Neoadjuvant Therapy.
J Thorac Oncol. 2023 Aug 3:S1556-0864(23)00685.
PubMed Abstract available

LIN SH
Statin Use and Chemoradiation in Esophageal Squamous Cell Carcinomas: Ready for Prime Time?
J Thorac Oncol. 2023;18:970-971.
PubMed

July 2023

RIMNER A, Ruffini E, Cilento V, Goren E, et al
The International Association for the Study of Lung Cancer Thymic Epithelial Tumors Staging Project: An Overview of the Central Database Informing Revision of the Forthcoming (Ninth) Edition of the TNM Classification of Malignant Tumors.
J Thorac Oncol. 2023 Jul 24:S1556-0864(23)00672.
PubMed Abstract available

June 2023

PIETROLUONGO E, De Placido P, Tortora M, Martinelli C, et al
Impaired seroconversion after SARS-CoV-2 mRNA vaccine in patients with thymic epithelial tumors.
J Thorac Oncol. 2023 Jun 28:S1556-0864(23)00634.
PubMed Abstract available

Thank you for your interest in scientific medicine.

AMEDEO Lung Cancer is free of charge.

Privacy / Datenschutzerklärung | Imprint / Impressum